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Abstract
This thesis considers the statistical modelling and analysis of proteomic
mass spectrometry data. Proteomics is a relatively new field of study and
tried and tested methods of analysis do not yet exist. Mass spectrometry
output is high-dimensional and so we firstly develop an algorithm to identify
peaks in the spectra in order to reduce the dimensionality of the datasets. We
use the results along with a variety of classification methods to examine the
classification of new spectra based on a training set. Another method to reduce
the complexity of the problem is to fit a parametric model to the data. We
model the data as a mixture of Gaussian peaks with parameters representing
the peak locations, heights and variances, and apply a Bayesian Markov chain
Monte Carlo (MCMC) algorithm to obtain their estimates. These resulting es-
timates are used to identify m/z values where differences are apparent between
groups, where the m/z value of an ion is its mass divided by its charge. A
multilevel modelling framework is also considered to incorporate the structure
in the data and locations exhibiting differences are again obtained.
We consider two mass spectrometry datasets in detail. The first consists
of mass spectra from breast cancer cells which either have or have not been
treated with the chemotherapeutic agent Taxol. The second consists of mass
spectra from melanoma cells classified as stage I or stage IV using the TNM
system. Using the MCMC and multilevel techniques described above we show
that, in both datasets, small subsets of the available m/z values can be identi-
fied which exhibit significant differences in protein expression between groups.
Also we see that good classification of new data can also be achieved using a
small number ofm/z values and that the classification rate does not fall greatly
when compared with results from the complete spectra. For both datasets we
compare our results with those in the literature which use other techniques on
the same data. We conclude by discussing potential areas for further research.
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Chapter 1
Thesis Outline and Background
Information
1.1 Thesis Outline
The research presented in this thesis is concerned with the analysis of pro-
teomic mass spectrometry data. Proteomics, the study of proteins and their
functions, is a relatively new field of research and thus there exist no tried and
tested methods of analysis.
In Chapter 2 we consider the problem of how to classify new spectra. Pro-
teomic datasets are generally high-dimensional and contain a relatively small
number of spectra. Having more observations per spectra than actual spectra
could result in perfect classifiers being obtained for the current data which do
not generalise to larger datasets. To reduce this problem, a deterministic peak
finding algorithm is developed in order to obtain a computationally cheap ap-
proximation of the data. The results of the algorithm allow some test spectra
to be classified based on a set of training spectra. Small groups of m/z values
are identified which provide high rates of correct classification.
In Chapters 3 and 4 we consider the problem of creating a parametric model
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for the mass spectra. Parametric modelling is another method by which we
can reduce the dimension of the problem. In chapter 3 Markov Chain Monte
Carlo (MCMC) methods are employed to model the datasets. A number of
related models, increasing in complexity, are considered and analysed. The
peak finding algorithm developed in chapter 2 is incorporated to provide a
suitable starting point for the MCMC algorithm. The resulting parameter
values are used to identify differences between different mass spectra which
are then compared with results obtained by other researchers. Some of this
research is published in Handley et al., (2005)
In chapter 4 we consider modelling the data using multilevel models. The
data have a natural hierarchical structure (m/z values within spectra) and
research in previous chapters has ignored this information. The peak finding
procedure from chapter 2 is again implemented to assist in the construction
of the fixed and random effects. For each group we fit a series of fixed effects
which model the average spectra for that group. Random effects are also in-
corporated in order that each spectrum can be modelled instead of simply the
average for each group. Differences between the groups will be identified by
considering the differences between fixed effects. A selection of m/z values are
obtained for each of the datasets which indicate where groups differ.
Lastly, in Chapter 5 we conclude by discussing the main results drawn from
this research. Also possible areas for further work are presented.
The results and graphics in this thesis have been obtained using the C++
programming language (Stroustrup, 2003) and the software packages R (R
Development Core Team, 2005) and MLwiN (Rasbash et al., 2000). Time
comparisons were calculated by using the high performance GRID computer.
2
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1.2 Background Information
Due to the high mortality rate of patients with advanced forms of the disease,
the detection of early stage cancer is of great importance. The identification
of indicators (biomarkers) which enable the progress of a disease to be mea-
sured is the subject of much research as there is the potential to diagnose
patients before they present with symptoms. Biomarkers assist in identifying
disease progression by providing quantitative information about molecules at
any given point in time. If the relative concentration of a particular molecule is
found to be different between healthy and diseased cases there is the potential
to use this information to diagnose disease. The identification of biomarkers
suitable for the early detection and diagnosis of cancer could greatly improve
patients’ diagnoses. Early detection of cancer could result in less severe, more
treatable diseases and ultimately higher cure rates.
Shown in table 1.1 are some examples of biomarkers already being used for
disease diagnosis (Diamandis, 2004). However, none of these biomarkers are
suitable for general cancer screening as they are not sufficiently specific and
lead to many false-positive results. Some of the procedures that are currently
used for general screening are mammography for breast cancer, pap smear for
cervical cancer and colonoscopy for colorectal cancer (Tibshirani et al., 2004).
Microarray technology is a popular method of expressing an entire genome
on a single chip by analysing mRNA. mRNA is genetic material created in the
nucleus of a cell. It is a copy of a small section of DNA (a gene) and contains
information which tells the cell how to synthesise proteins. The expression lev-
els of many thousands of genes can be simultaneously studied and differences
in relative expressions can be used to infer differing disease states. However,
proteins are considered closer to actual biological functions than mRNA and,
since mRNA concentration correlates poorly with protein concentration (Ya-
sui et al., 2003), it is more useful to look for protein biomarkers for disease.
This is not possible using microarrays and so the need for large scale analy-
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biomarker cancer type
α-Fetoprotein (AFP) hepatoma; testicular
Carcinoembryonic antigen (CEA) colon; breast; lung; pancreatic
Prostate specific antigen (PSA) prostate
CA125 ovarian
CA15.3 breast
CA19.9 gastrointestinal
Immunoglobins B cell dyscrasias
Chroriogonadotrophin testicular; trophoblastic tumours
Steroid hormone receptors breast
Table 1.1: Examples of established cancer biomarkers.
sis of proteins led to the new research area of proteomics which is concerned
with characterising all the proteins in a biological sample. Nearly all useful
biomarkers identified thus far have been proteins (Robbins et al., 2005).
The traditional method for discovering disease-associated proteins was
by using two-dimensional polyacrylamide gel electrophoresis (2D-PAGE), in-
vented by O’Farrell and Klose in 1975 (O’Farrell, 1975 and Klose, 1975). This
method separates proteins onto a gel by pH level and size, and gels can then
be compared between two or more disease groups. The large number of studies
carried out using this method has enabled databases to be created of disease-
associated proteins. Some studies that have used this method are, for example,
Edwards et al. (1982), Adam et al. (2001) and Srinivas et al. (2001) which
between them cover prostate and bladder cancers. Although 2D-PAGE is able
to resolve thousands of proteins and detect differences in protein expression,
it is labour intensive and requires high abundance of the proteins in question.
Also some types of proteins - hydrophobic, strongly acidic or strongly basic -
are poorly resolved (Poon et al., 2003). Nearly all common cancer biomarkers
have a concentration of 1 ng/mL or less which is below the detection limit
for 2D-PAGE and thus no new biomarkers for cancer arose from this method
(Robbins et al., 2005).
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An advance in the study of proteins was made in 1987 with the devel-
opment of matrix assisted laser desorption/ionisation time-of-flight (MALDI-
TOF) mass spectrometry. Mass spectrometry is a technique used to identify
and measure a wide variety of biological and chemical compounds. It works
on the principle that different molecules have different masses and thus by
separating a substance into its constituents according to their mass we can
identify which molecules are present. Mass to charge ratios of up to 50,000 Da
can be resolved using this method (Yanagisawa et al., 2003).
Surface enhanced laser desorption/ionisation time-of-flight (SELDI-TOF)
mass spectrometry, originally described by Hutchens and Yip (1993), is a novel
development in time-of-flight mass spectrometry. The general principle behind
SELDI-TOF is that proteins of interest from biological samples bind selectively
to a chemical surface, and the impurities are then washed away. This remaining
part of the sample is then complexed with an energy absorbing molecule, and
analysed by laser desorption/ionisation time-of-flight mass spectrometry to
determine the abundance of the different molecules present in the sample.
The results are often displayed as a graph showing the relative abundance
associated with protein mass/charge (m/z ) ratios over a particular Dalton
range (see figure 1.1). The main advantage of TOF methods over 2D-PAGE
is their ability to detect molecules with m/z ratios smaller than 20 kDa (Qu
et al., 2002).
Many different methods have been employed in recent years to analyse mass
spectrometry data. Genetic algorithms are used by Petricoin et al. (2002) to
study ovarian cancer and artificial neural networks (ANN) by Zhang et al.
(1999) and Mian et al. (2003) to study pelvic masses and breast cancer re-
spectively. T-statistics are quite popular and are used, for example, by Chen
et al. (2002), Vlahou et al. (2001) and Xiao et al. (2001) to study lung ade-
nocarcinoma, bladder cancer and prostate cancer respectively. Also random
forests are used by Izmirlian (2004) and decision trees by Adam et al. (2002)
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Figure 1.1: An example of a SELDI-TOF mass spectrum.
to study prostate cancer.
The SELDI-TOF method has also been used in some non-cancer settings.
Nomura et al. (2004) use the method to search for biomarkers for alcoholism.
Uchida et al (2002) study a dataset on rheumatoid arthritis and actually iden-
tify one of the biomarkers they find in their analysis as a protein known to
be related to the disease. This shows promise for the future of identifying
biomarkers by this method.
However, questions have been asked regarding the impressive results quoted
in the literature obtained using these proteomic methods. There appear to be
four main objections. Firstly, Baggerly et al.(2004) question the reproducibil-
ity of the results. They analyse the same data as Petricoin et al. (2002) but are
unable to replicate most of their findings as two of the datasets have been back-
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ground subtracted. This is a process by which electronic noise inherent in the
mass spectrometer is removed from the resulting mass spectrum. Background
subtraction is an irreversible, non-linear operation and thus the original values
cannot be reconstructed. Note that in figure 1.1 there are some negative inten-
sities near the beginning of the spectrum. This is due to the data having been
background subtracted. It is also suggested that changes in the laboratory, the
mass spectrometer or the ProteinChip array could alter the results obtained.
A recent study by Munro et al. (2006) is the first to have demonstrated the
reproducibility of their results. A random forest classifier was used to predict
the presence of transitional cell carcinoma (TCC) and initial results indicated
71.7% sensitivity and 62.5% specificity. When an independent validation set
was studied 6 months later the respective results were 78.3% and 65.0% which
are comparable with tests currently being used to diagnose TCC.
Secondly, both Baggerly et al. (2004) and Sorace and Zhan (2003) ques-
tion the use of m/z values below 2,000 Daltons. Such m/z values are generally
considered to be noise and should be excluded from any analysis. In the paper
by Petricoin et al. (2002) classifiers solely in the noise region are obtained that
classify the data perfectly. One particular example is found with an m/z value
of 2.79 Daltons suggesting an experimental bias not related to disease state.
Thirdly, Banks et al. (2005) conclude that sample handling can have a
marked effect on the spectra obtained from time-of-flight mass spectrometry.
The time elapsed between obtaining the sample and processing it was a main
cause of differences although others included temperature, storage and cen-
trifugation (time and speed).
Lastly, Somorjai et al. (2003) believe that the near-perfect classification
rates quoted in the literature are misleading and believe this is due to two
reasons - too many m/z values and not enough spectra. With such a large
7
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number of m/z values corrections must be made for multiple measurements
using, for example, Benjamini and Hochberg’s (1995, 2000) false discovery rate
approach. Also seemingly robust classifiers can be obtained relatively easily if
there are only a few examples per group available. Future experiments should
obtain as many examples in each group as is practical to reduce this problem.
1.3 The Datasets
The two datasets analysed in this thesis result from mass spectrometric anal-
ysis of breast cancer and melanoma cell lines respectively.
A cell-line consists of cells of a single type taken from an animal or human
and grown in the laboratory. These cells can grow and replicate continuously
outside the living organism and, with the proper conditions, may be kept alive
indefinitely in a Petri dish. All the cells are genetically identical to a single
common ancestor cell which makes them valuable for research.
Breast cancer is cancer of breast tissue and is the most common form of
cancer in females. In the Western world it will affect approximately one in
nine women at some stage of their life (Markham, 2005).
The breast cancer dataset consists of 144 cell-lines divided equally into one
of three groups. The first group consists of 48 cell-lines of the type MCF-
7/ADR which are chemoresistant and the second and third groups each con-
sist of 48 chemosensitive cell-lines of the types T47D and MCF-7 respectively.
Half of the cell-lines in each group have received a 24 hour exposure to the
chemotherapeutic agent Taxol.
Taxol (Paclitaxel) is a drug used in the treatment of cancer. It was isolated
by Drs. M.E. Wall and M.C. Wani in 1967 (from yew tree bark), who originally
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studied its therapeutic activity in rodent tumours (Wani et al., 1971). One of
the most common characteristics of cancer cells is that they divide rapidly and
Paclitaxel acts by inhibiting this cell replication. Paclitaxel can now be made
in the laboratory and is sold under the tradename Taxol.
Each half of each group in the breast cancer dataset contains three repli-
cates at each of 4 time intervals for two experiments. Note that as the MCF-
7/ADR cell-lines are chemoresistant they should not be affected by the Taxol
treatment.
The breast cancer data are shown in figure 1.2 as images. Results for m/z
values below 2,000 Daltons have been removed as background interference from
sinapinic acid matrix peaks tend to produce low signal:noise ratios (Ball et al,
2002).
In summary there are six groups: ADC (MCF-7/ADR control), ADT
(MCF-7/ADR Taxol treated), TDC (T47D control), TDT (T47D Taxol
treated), MCC (MCF-7 control) and MCT (MCF-7 Taxol treated). SELDI-
TOF scans were taken at periods of 24, 48, 72 and 96 hours and these are
labelled as day 1, day 2, day 3 and day 4 respectively. For each group on
each day there are 6 observations: replicates A,B and C for experiment 1 and
replicates A,B and C for experiment 2.
The protocol for the experiment is described in detail by Mian et al. (2003),
and the data were collected at Nottingham Trent University in the laboratory
of Professor Robert Rees.
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Figure 1.2: The breast cancer data. The x-axis shows m/z value starting at
2,001 Daltons and finishing at 30,000 Daltons. For each group at each m/z
value there are 6 observations presented in the order (bottom to top) replicates
A,B,C for experiment 1 followed by replicates A,B,C for experiment 2. Green
indicates a low level of protein intensity increasing through blue and red to
the highest intensity of yellow.
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Melanoma is a malignant tumour of the skin and is made up of cells contain-
ing the pigment melanin. It is not very common - accounting for only about
4% of all cancer cases, however, it is one of the most serious, life-threatening
forms of skin cancer accounting for 79% of skin cancer deaths (Kirkwood et
al., 2003). It begins in the cells that produce the skin colouring and often
appears on the skin as a new or changing mole. Melanomas are induced by
exposure to high levels of UV radiation and are more common in people who
have had significant sun exposure. Early stage melanoma is almost always
curable, however, it is likely to spread, and once it has spread to other parts
of the body the chances of a cure are much less.
The melanoma dataset consists of 205 sera - 101 of these are classed as
stage I of the disease and 104 are classed as stage IV using the Tumour-lymph
Node-Metastasis (TNM) system (e.g. Sobin and Wittekind, 2002). Each of
these categories is given a number as per table 1.2. A lower number generally
means a less serious melanoma. The value of each category is used to stage
the melanoma by comparing with table 1.3.
The melanoma data are shown in figure 1.3 as images. As previously the
m/z values below 2,000 Daltons have been removed.
The mass spectrum for a cell-line in either of the datasets consists of around
14,000 datapoints. Each datapoint comprises a relative intensity of proteins
at a particular mass over charge (m/z value). The m/z value is calculated by
dividing the protein mass by the number of charges induced by ionisation. We
consider m/z values between 2kDa and 30kDa.
The experimental protocol is described in detail in Mian et al. (2005). The
data were collected at the German Cancer Research Centre, Heidelberg in the
laboratory of Dr. Dirk Schadendorf.
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TNM What it means
T0 There is no evidence of a tumour.
Tis Melanoma has some of the changes that make it
cancer, but it is not yet the kind that spreads into
T other tissues. This is also called melanoma in situ.
(tumour) T1 Melanoma is 1 millimetre or less in thickness.
T2 Melanoma is between 1 and 2 millimetres thick.
T3 Melanoma is between 2 and 4 millimetres thick.
T4 Melanoma is more than 4 millimetres thick.
N0 Melanoma has not spread to any lymph nodes.
N N1 Melanoma has spread to one lymph node nearby.
(lymph N2 Melanoma has spread to two or three lymph nodes
nodes) nearby.
N3 Melanoma has spread to four or more lymph nodes
nearby.
M M0 Melanoma has not spread to another part of the body.
(metastasis) M1 Melanoma has spread to another part of the body.
Table 1.2: TNM classes for melanoma.
TNM Cancer Stage
Tis, N0, M0 0
T1, N0, M0
I
T2, N0, M0
T2, N0, M0
T3, N0, M0 II
T4, N0, M0
Any T, N1, M0
Any T, N2, M0 III
Any T, N3, M0
Any T, Any N, M1 IV
Table 1.3: Stages of melanoma. Note that T2,N0,M0 can be classed as either
stage I or stage II depending on its appearance under a microscope.
12
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stage I
stage IV
Figure 1.3: The melanoma data. The x-axis shows m/z value starting at 2,001
Daltons and finishing at 30,000 Daltons. For stage I there are 101 observations
and for stage IV there are 104 observations. Green indicates a low level of
protein intensity increasing through blue and red to the highest intensity of
yellow.
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1.4 Data Reduction and Classification
Presented in this section are the methods used in this thesis to classify obser-
vations and the two main techniques used to reduce the dimensionality of a
dataset.
It is important to consider data reduction in proteomic studies. The
datasets produced by time-of-flight mass spectrometry are generally high-
dimensional and there are generally many more m/z values per spectrum than
there are spectra.
1.4.1 Dimension Reduction Methods
Principal Components Analysis
The main goal of principal components analysis (PCA) is to explain the impor-
tant variability in the data in a reduced number of dimensions. This is done
by projecting the data linearly onto lower dimensional subspaces in which they
show maximal variation. We describe sample principal components analysis
where a sample of vectors x1 . . . ,xn is available.
Let u be a unit vector i.e. uTu = 1. Define ci = u
T (xi − x¯) for i = 1 . . . n
where the x′is are column vectors of observations, x¯ =
1
n
∑n
i=1 xi is their sample
mean and n is the number of observations. Now
n∑
i=1
ci =
n∑
i=1
uT (xi − x¯) = uT
n∑
i=1
(xi − x¯) = 0
by definition of x¯, and
1
n
n∑
i=1
c2i =
1
n
n∑
i=1
uT (xi − x¯)(xi − x¯)Tu
= uT
[
1
n
n∑
i=1
(xi − x¯)(xi − x¯)T
]
u
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= uT S¯u. (1.1)
So uT S¯u is the sample variance of the ci’s along u. We would like to find
the u∗ which maximises the sample variance uT S¯u over unit vectors u.
Since S¯, the sample covariance matrix of the observations, is symmetric,
applying spectral decomposition (e.g. Mardia, Kent and Bibby, 1979) gives:
S¯ = QΛQT =
p∑
j=1
λjqjq
T
j
whereQ = [q1,q2, . . . ,qp],QQ
T = QTQ = Ip andΛ = diag{λ1, λ2, . . . , λp}.
The vectors qj are the eigenvectors corresponding to the eigenvalues λj,
where j = 1 . . . p. Without loss of generality assume that λ1 ≥ λ2 ≥ . . . ≥ λp.
Then
uT S¯u = uT
[
p∑
j=1
λjqjq
T
j
]
u
=
p∑
j=1
λju
Tqjq
T
j u
=
p∑
j=1
λj(u
Tqj)
2 since uTqj is a scalar
≤ λ1
p∑
j=1
(uTqj)
2 since λ1 is the largest eigenvalue
= λ1u
TQIpQ
Tu
= λ1u
Tu
= λ1 since ‖u‖ = 1 (1.2)
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but
qT1 S¯q1 = q
T
1
[
p∑
j=1
λjqjq
T
j
]
q1
=
p∑
j=1
λj(q
T
1 qj)
2
= λ1. since q
T
1 qj =
{
0 j 6= 1;
1 j = 1.
(1.3)
So uT S¯u is maximised over unit vectors u when u = q1 i.e. the unit eigen-
vector corresponding to the largest eigenvalue λ1. The largest eigenvector is
unique up to sign when λ1 > λ2.
This procedure can be repeated to look for the largest sample variance of
the ci’s when u is chosen to be orthogonal to q1 (i.e. when u
Tq1 = 0). Similar
reasoning shows that this occurs when u = q2, the eigenvector corresponding
to the second largest eigenvalue λ2 (e.g. Mardia, Kent and Bibby, 1979).
The values q1,q2, . . . ,qp determine the p principal components (p ≤ n−1).
The sji are the PC scores where
sji = q
T
j (xi − x¯) i = 1 . . . n, j = 1 . . . p.
Independent Components Analysis
Independent Components Analysis (ICA) was introduced in the early 1980s in
the context of neural network modelling and was developed in the 1990s with
the introduction of new algorithms. ICA has been used in such applications
as telecommunications, time series analysis and data mining.
ICA is a statistical technique in which observed random data are expressed
as a linear combination of components that are statistically independent from
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each other. Such a decomposition is well defined if the independent compo-
nents are non-Gaussian (Hyva¨rinen et al, 2001).
Assume we observe n random variables (spectra) x1, . . . , xn which we wish
to model as linear combinations of the n random variables s1, . . . , sn. Then
xi = ai1s1 + ai2s2 + . . . ainsn, for all i = 1, . . . , n
where the aij (i, j = 1, . . . n) are some real coefficients. The random variables
sj are called the independent components (ICs). By definition the sj are statis-
tically mutually independent. The values of the sj ’s and the aij ’s are unknown
and must be estimated from the observed data xi.
This model is written in matrix notation as follows. Let x be the random
vector consisting of the xi and s be the vector consisting of the sj. Let A be
the matrix with elements aij . Then the model becomes
x = As =
n∑
i=1
aisi (1.4)
where ai is the i
th column of the matrix A.
When using ICA we assume that the ICs are statistically independent, that
the ICs have non-Gaussian distributions and that the matrixA must be square
(same number of ICs as xi’s) and invertible. This last restriction can some-
times be relaxed (see Hyva¨rinen, 2001) but if it holds then we can calculate
the inverse A−1 = B and obtain the ICs simply by s = Bx
There are two problems encountered with this ICA model. Firstly we
cannot determine the variances of the ICs. Since A and s are both unknown,
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a scalar multiplier in one can be cancelled out in the other:
x =
n∑
i=1
aisi =
n∑
i=1
1
αi
ai(siαi)
Secondly we cannot determine the order of the ICs. Again, since A and s are
both unknown, the order of the terms in equation (1.4) can be rearranged and
any one of them can be called the first. In practice the matrix B = A−1 is
estimated by calculating the vectors bj which maximise the non-Gaussianity
of the calculated sj. Many algorithms exist which carry out ICA and in this
thesis the FastICA algorithm is used in R.
1.4.2 Classification Methods
After dimension reduction has been carried out we can use the new variables to
classify new observations into different disease states. This could be important
to physicians when determining which treatment to give different patients.
Three of the main methods for classifying data are now described.
Discriminant Analysis
In discriminant analysis there exist G ≥ 2 populations. It is assumed that
each population has a particular distribution fi(x) ∈ Rp (i = 1, . . . G). A set
of data x1, . . . ,xn is available for which the group membership of each obser-
vation is known. These are called the training data. Based on the assumptions
and the training data, rules are constructed for assigning a new observation
z ∈ Rp to one of the G populations whilst minimising the probability of mis-
classification. The aim is to find an effective rule for discrimination based on
inexpensive measurements instead of near-perfect classification using expen-
sive measurements. An approach due to Fisher (1936) is to look for a linear
discriminant function without assuming that the G populations Π1,Π2, . . . ,ΠG
are normally distributed.
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Suppose we have training samples xi1,xi2, . . . ,xini from population Πi, i =
1 . . .G. Then the ‘within’ sum of squares covariance matrix is
W =
G∑
i=1
ni∑
j=1
(xij − x¯i)(xij − x¯i)T where x¯i = 1
ni
ni∑
j=1
xij
and the ‘between’ sum of squares covariance matrix is
B =
G∑
i=1
ni(xi − x¯)(xi − x¯)T where x¯ = 1
N
G∑
i=1
ni∑
j=1
xij and N =
G∑
i=1
ni
Fisher’s criterion is to choose a unit vector λ to maximise
λTBλ
λTWλ
. (1.5)
Then the function L(z) = λTz is called Fisher’s linear discriminant function.
To find λ to maximise equation (1.5) assume that W is positive definite and
note that W is symmetric. So using spectral decomposition (e.g. Mardia,
Kent and Bibby, 1979) gives W = QΛQT and W1/2 = QΛ1/2QT where
n×n
Λ = diag{µ1, µ2, . . . , µn} are the eigenvalues of W and
n×n
Q is an orthogonal
matrix whose columns are the eigenvectors of W.
Define γ =W1/2λ, then λ =W−1/2γ where W−1/2 = QΛ−1/2QT . Now
max
λ:λλT =1
{
λTBλ
λTWλ
}
= max
γ:γ 6=0


γTW−1/2BW−1/2γ
γT W−1/2WW−1/2︸ ︷︷ ︸
Ip
γ


= max
γ:γT γ=1
{
γTW−1/2BW−1/2γ
}
(1.6)
To solve this maximisation choose γ to be the eigenvector corresponding to
the largest eigenvalue ofW−1/2BW−1/2. This is true since if γ is an eigenvector
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of W−1/2BW−1/2 then by definition
W−1/2BW−1/2γ = ργ
for some constant ρ. If we premultiply by W−1/2 we get the following:
W−1/2W−1/2BW−1/2γ = ρW−1/2γ
W−1B
[
W−1/2γ
]
= ρW−1/2γ
⇒ W−1Bλ = ρλ (1.7)
So the λ required is the unit eigenvector corresponding to the largest eigen-
value of W−1B. Fisher’s linear discriminant function L(z) can now be calcu-
lated and an observation z will be allocated to the Πi whose discriminant score
L(x¯i) is closest to L(z) i.e.
allocate z to Πi iff |λTz− λT x¯i| = min
1≤j≤G
|λTz− λT x¯j|
In linear discriminant analysis, the covariance matrix of each group is as-
sumed to be equal. In this case the decision boundaries calculated from the
above equations are linear. If this assumption is not true then quadratic
discriminant analysis (QDA) can be used and the decision boundaries are
quadratic curves. QDA provides superior results if the group covariances are
considerably different and the group sizes are large. However, QDA is more
sensitive to deviations from normality and classification errors in the training
set (Lachenbruch, 1982).
Support Vector Machines
Support vector machines (SVMs) were introduced by Boser, Guyon and Vap-
nik (1992) as a means of classifying data. They have been used in many fields
including bioinformatics and image recognition. The simplest SVM is called
the maximal margin classifier and only works for data that can be linearly
20
1.4 Data Reduction and Classification
separated and is therefore not valid in many real life situations. However, in
1995 a modified maximum margin idea was suggested for when the datapoints
cannot be separated without error (Cortes and Vapnik, 1995). If no linear
classifier exists that can correctly split the datapoints, the soft margin method
will choose a classifier that splits the datapoints as cleanly as possible, while
still maximising the distance to the nearest cleanly split datapoints.
The margin of a linear classifier is defined to be the width that the bound-
ary could be increased before hitting any datapoints. In figure 1.4, for example,
the classifier on the left has a smaller margin than the classifier on the right
as extending the line will reach the point at (6, 9.5) more quickly.
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Figure 1.4: Two linear classifiers with different margins.
The classifier with the largest margin is called the maximum margin linear
classifier and the support vectors are the datapoints that the maximum mar-
gin pushes up against. The use of maximum margin classifiers gives the least
chance of causing a misclassification if there is a small error in the location of
the boundary.
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The equation of the maximum margin linear classifier in N dimensions is
of the form
βTx+ β0 = 0
and the distance from the classifying boundary to the nearest points is C. We
wish to maximise the distance C whilst allowing for some datapoints to be on
the wrong side of the boundary. We define the slack variables ξ1, . . . , ξN as
the amounts that the datapoints xi, i = 1, . . . , N are on the wrong side of the
margin. We also wish to minimise the sum of these errors. The maximisation
to be calculated is:
max
β0,β,‖β‖=1
C (1.8)
subject to the conditions yi(x
T
i β + β0) ≥ C(1 − ξi), i = 1, . . . , N, ξi ≥
0,
∑N
i=1 ξi ≤ constant , where the xi are the datapoints and the yi denote to
which class the xi belong. Note misclassifications occur when ξi > 1. We can
remove the ‖β ‖ = 1 constraint by replacing the first condition with
yi(x
T
i β + β0) ≥ C‖β‖, i = 1, . . . , N
Since any scalar multiples of β and β0 also satisfy the inequalities, we can
choose to set ‖β ‖ = 1/C. So equation (1.8) is equivalent to
min
β0,β
1
2
‖β‖2 + γ
N∑
i=1
ξi (1.9)
subject to yi(x
T
i β+β0) ≥ C(1−ξi), i = 1, . . . , N, ξi ≥ 0. To solve this con-
strained minimisation we use the Lagrange multiplier technique (e.g. Winston,
1995). The Lagrangian is
1
2
‖β‖2 + γ
N∑
i=1
ξi −
N∑
i=1
λi
[
yi
(
xTi β + β0
)− (1− ξi)]− N∑
i=1
µiξi (1.10)
Differentiating equation (1.10) with respect to β0 and setting equal to zero
gives
∑N
i=1 λiyi = 0, differentiating with respect to β gives
∑N
i=1 λiyixi = β and
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differentiating with respect to ξi gives λi = γ−µi, ∀i. (Note that λi, µi, ξi ≥ 0).
Substituting these results into 1.10 gives
1
2
‖β‖2 + γ
N∑
i=1
ξi −
N∑
i=1
λiyix
T
i β −
N∑
i=1
λiyiβ0 +
N∑
i=1
λi −
N∑
i=1
λiξi −
N∑
i=1
µiξi
=
1
2
N∑
i=1
N∑
k=1
λiλkyiykx
T
i xk + γ
N∑
i=1
ξi −
N∑
i=1
N∑
k=1
λiλkyiykx
T
i xk −
N∑
i=1
λiyiβ0
+
N∑
i=1
λi −
N∑
i=1
γξi +
N∑
i=1
µiξi −
N∑
i=1
µiξi
=
1
2
N∑
i=1
N∑
k=1
λiλkyiykx
T
i xk −
N∑
i=1
N∑
k=1
λiλkyiykx
T
i xk +
N∑
i=1
λi
=
N∑
i=1
λi − 1
2
N∑
i=1
N∑
k=1
λiλkyiykx
T
i xk (1.11)
Although this leaves us with another optimisation, equation (1.11) can be
minimised more easily than the original problem. Firstly we differentiate and
solve equation (1.11) for each λi. Then β can be determined from the equation∑N
i=1 λiyixi = β.
To determine β0 we must use the Karush-Kuhn-Tucker condition (e.g. Win-
ston, 1995)
λi[yi(x
T
i β + β0)− (1− ξi)] = 0 ∀i. (1.12)
There must exist at least one support vector xi. For all support vectors ξi = 0
as they lie on the margin. Substituting in our known values relevant to one
support vector gives us the equation of the classifier. Test points can then be
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classified according to the side of the boundary on which they fall.
Although the classifier has been constructed in order that no training points
fall within the margin, this may not necessarily hold for test points. It is hoped
that a large margin separating the training data will give good test classifica-
tion. When there are more than two groups into which points can be classified
more than one linear classifier must be trained. In this thesis the ‘one against
one’ approach is used where, with k groups, each of the k(k − 1)/2 pairwise
comparisons are considered and a voting scheme determines the classification
of a test point.
K-Nearest-Neighbour
The K-nearest neighbour (KNN) algorithm is a relatively simple method for
classifying observed data where class memberships are known for a set of train-
ing data. For a particular observed datapoint the nearest K training points,
usually using Euclidian distance, are considered and a majority vote of their
K classes is taken as the class of the new datapoint. If there is a tie then
it is broken at random between the tied groups. The accuracy of the KNN
algorithm can be severely affected by the presence of outliers, especially when
K = 1. The best choice of K depends upon the data. Generally, larger values
ofK reduce the effect of noise on the classification, but the boundaries between
classes become less distinct. See Hastie et al. (2001) for further details.
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1.5 MCMC for Bayesian Inference
The use of Bayesian methods in applied problems increased greatly at the end
of the 20th century. The availability of fast computers was combined with the
development of Markov Chain Monte Carlo (MCMC) algorithms, a group of
simulation methods, which allowed the study of more complex Bayesian mod-
els. The idea behind MCMC is to simulate approximate samples from the
posterior distribution of interest by generating a Markov chain which has the
posterior distribution as its limiting equilibrium distribution. This approach
originated in the statistical physics literature (Metropolis et al., 1953) and it
was then generalised by Hastings (1970). However, it was Gelfand and Smith
(1990) that brought MCMC methods to the attention of the general statistical
community, and since then the use of Bayesian methods for applied statistical
modelling has increased rapidly.
Gilks et al. (1996) gives an overview of advances in MCMC related method-
ology until 1995. MCMC software is also being produced and made freely
available to analyse a wide range of statistical models. An example is BUGS -
Bayesian inference Using Gibbs Sampling (see Spiegelhalter et al., 1996). We
will use MCMC in chapter 3.
1.5.1 Bayesian Inference
The fundamentals of Bayesian theory are reviewed in this section in an in-
troductory manner. For a more detailed approach see Bernardo and Smith
(1994).
Bayes’ Theorem
In classical inference the data, which are assumed to depend on a vector of
parameters, θ, are thought of as random with θ fixed (but unknown). In
Bayesian inference the thinking is opposite - the data are regarded as fixed (at
what has been observed) and the parameter vector θ is treated as unknown.
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In the Bayesian approach in addition to specifying the model for the ob-
served data y = (y1, . . . , yn) given the vector of unknown parameters θ, in the
form of the likelihood function π(y|θ), we also define the prior distribution
π(θ). The prior should contain all knowledge we have about the unknown
parameter before analysis starts. Inference concerning θ is then based on its
posterior distribution, given by
π(θ|y) = π(y|θ)π(θ)∫
π(y|θ)π(θ)dθ ∝ π(y|θ)π(θ). (1.13)
This formula is referred to as Bayes’ Theorem. The integral in the denomina-
tor is a normalising constant to ensure the distribution is a valid probability
distribution and it’s calculation has traditionally been a computational obsta-
cle. The main difficulty is that the calculation involves a many-dimensional
integration and the resulting distribution cannot always be written down in
closed form. However, it is possible to avoid its calculation using MCMC
methods. Equation (1.13) can be thought of as “The posterior is proportional
to the likelihood times the prior”.
Prior Distributions
Presented here are the two most popular approaches for choosing a prior dis-
tribution.
Informative priors
An informative prior for a parameter θ is a prior used when some information is
known about the parameter before any data is obtained. For example, assume
we were interested in estimating the average weight of newborn female babies.
Then before we actually collect any observations of the weight of newborn
babies, we find on a website that the average weight of a newborn is 3.4 kg. A
prior is then chosen to incorporate this information - we choose a normal prior
with mean 3.4 and variance σ2. The value of σ2 is still to be chosen and will
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incorporate the strength of our belief in the mean value of 3.4. The lower the
value of σ2, the stronger our belief in the mean. If we believe female babies
to weigh less than male babies we can also include this belief by reducing our
mean value.
Non-Informative or Diffuse Priors
In many situations no prior information concerning θ is available, or inference
based solely on the data is desirable. Typically in this case we wish to define
a prior distribution π(θ) that contains no information whatsoever about the
parameter θ in the sense that it does not favour one particular value of θ over
another. Such a distribution is called a noninformative prior for θ and it can
be argued that the information about θ contained in the posterior comes only
from the data. In classical inference prior distributions are not used in fitting
models and so ‘noninformative’ priors are often used in Bayesian inference to
compare with classical results.
In the case where the parameter space is Θ = {θ1, . . . , θn} i.e. discrete and
finite, then the distribution
π(θi) =
1
n
, i = 1, . . . , n
places the same prior probability of 1/n on any of the n candidate θ values.
Similarly, in the case of a bounded continuous parameter space, say
Θ = [a, b],−∞ < a < b <∞, then the uniform distribution
π(θ) =
1
b− a, a < θ < b
is noninformative. A normal distribution with large variance may also be
used as a noninformative prior. As the variance of a normal distribution is
increased, the distribution becomes ‘flatter’ around the mean (see figure 1.5).
This explains the alternative names for noninformative priors of ‘flat’ or ‘dif-
fuse’ priors.
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Figure 1.5: Normal distributions with mean 0 and variances 1, 5, 10, 20 and
100 respectively.
For unbounded intervals the definition of a noninformative distribution is
not straightforward. In the case that Θ = (−∞,∞) a distribution such as
π(θ) = c is clearly improper since
∫
π(θ)dθ =∞. However, Bayesian inference
is still possible in the case where
∫
π(y|θ)dθ = D <∞. Then
π(θ|y) = π(y|θ)c∫
π(y|θ)cdθ =
π(y|θ)
D
.
It should be noted that there is not a ‘universal’ noninformative prior. It
is possible in some cases for a constant prior to actually be informative under
a different parameterisation. One method used to overcome this problem is
the use of Jeffreys prior. Jeffreys prior (1946) takes the form π(θ) ∝ I(θ)1/2,
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where
I(θ) = E
[[
∂
∂θ
log π(y|θ)
]2]
is the Fisher information.
When choosing a prior from a parametric family it can be possible to select
a distribution which is conjugate to the likelihood, that is one that leads to a
posterior belonging to the same family as the prior. The use of MCMC does
not require conjugate priors but they can be computationally convenient.
1.5.2 Markov Chain Monte Carlo
We will now consider a collection of algorithms that greatly facilitate the im-
plementation of Bayesian modelling known as Markov Chain Monte Carlo
(MCMC) algorithms.
Suppose a sequence of random variables {X0, X1, X2, . . .} is generated such
that at each time t ≥ 0, the next state Xt+1 is sampled from a distribution
P (Xt+1|Xt) which depends only on the current state of the chain Xt. So given
Xt, the next state Xt+1 does not depend on the remainder of the history of
the chain {X0, X1, . . . , Xt−1}. This sequence is called a Markov chain.
The main idea behind MCMC is to generate a Markov chain which has as
its limiting equilibrium distribution the posterior distribution of interest. For
MCMC to work the chain must be aperiodic, irreducible and reversible (Gilks
et al., 1996). MCMC first appeared in Metropolis et al. (1953) although
the computational power was not available then to carry out many of the
procedures used today. The original mechanism was generalised by Hastings
(1970) in the Metropolis-Hastings algorithm, which is now described.
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The Metropolis-Hastings Algorithm
The objective of the Metropolis-Hastings (MH) algorithm is to generate ap-
proximate samples from a posterior density π(θ|y) known up to a normalising
constant. For this algorithm, at each time t, the next state θ(t+1) is chosen
by first sampling a candidate point φ from a proposal distribution q(.|θ(t)).
Note that the proposal distribution may depend on the current state θ(t). The
candidate point is then accepted with probability α(θ(t), φ) where
α(θ(t), φ) = min
{
1,
π(φ|y)q(θ(t)|φ)
π(θ(t)|y)q(φ|θ(t))
}
If a candidate point is accepted, the next state becomes θ(t+1) = φ and if the
candidate point is rejected the chain remains in the same place i.e. θ(t+1) = θ(t).
So the algorithm generates a Markov chain (θ(t)) through the following steps:
1. Start with an arbitrary initial set of parameter values θ(0).
2. Update from θ(t) to θ(t+1) (t = 0, 1, . . .) by
(a) Generate φ ∼ q(.|θ(t))
(b) Evaluate α(θ(t), φ) = min
{
1,
π(φ|y)q(θ(t)|φ)
π(θ(t)|y)q(φ|θ(t))
}
(c) Sample a point U from a Uniform(0, 1) distribution.
(d) Set
θ(t+1) =
{
φ If U ≤ α(θ(t), φ);
θ(t) otherwise.
Metropolis-Hastings updates can be carried out in different ways. Firstly all
the parameters can be updated at the same time so the candidate point φ
would become a vector of parameters. Either all the parameters are accepted
or they are all rejected. Secondly, they can be updated one parameter at a
time and each iteration t would comprise of n updates (where there are n
parameters). Lastly a combination could be used where the parameters are
split into blocks and each block of parameters is updated at the same time.
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The Gibbs Sampler
The Gibbs sampling approach is a special case of the Metropolis-Hastings al-
gorithm. The method derives its name from Gibbs random fields, where it was
used for the first time by Geman and Geman (1984).
Suppose we have a vector θ consisting of n parameters θ1, . . . , θn. Consider
the conditional density of θi given the data y and all the other elements of
θ. Let θ(−i) be the vector θ with element θi removed. Then the distributions
πi(θi|θ(−i), y) for i = 1, . . . , n are called the full conditional distributions of
π(θ|y).
The idea of Gibbs sampling is to sample from the joint posterior distribution
π(θ1, θ2, . . . , θn|y) using the full conditional distributions. The parameters θi
are updated by sampling from each of the full conditionals in turn, cycling
round the parameters in each iteration. Start with an initial parameter vector
θ(0) and then generate θ(1), θ(2), . . . as follows. Given the current state of the
chain θ(t) = (θ
(t)
1 , ..., θ
(t)
n )
Generate θ
(t+1)
1 from π(θ1|θ(t)2 , θ(t)3 , θ(t)4 , ..., θ(t)n , y)
Generate θ
(t+1)
2 from π(θ2|θ(t+1)1 , θ(t)3 , θ(t)4 , ..., θ(t)n , y)
Generate θ
(t+1)
3 from π(θ3|θ(t+1)1 , θ(t+1)2 , θ(t)4 , ..., θ(t)n , y)
:
Generate θ
(t+1)
n from π(θn|θ(t+1)1 , θ(t+1)2 , θ(t+1)3 , ..., θ(t+1)n−1 , y)
We now have the next state in the chain θ(t+1). The distribution of θ(t)
tends to π(θ|y).
The Gibbs sampler is a special case of the Metropolis-Hastings sampler
and has acceptance probability 1. Assume again that we have parameters
θ1, . . . , θn and we wish to estimate the posterior density π(.). The proposal
distribution in a Gibbs sampling update is the full conditional distribution of
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the parameter i.e. q(θi|θ−i) = πi(θi|θ−i). Let θ = (θt1, . . . , θtn) be the current
state of the chain and let θ′ = (θt+11 , . . . , θ
t
n) be the proposed state of the chain
when updating parameter θ1. Note that the full conditional distribution of the
parameter θ1 can be expressed through the following equation:
π(θ1, θ2 . . . , θn) = π1(θ1|θ2 . . . , θn)π(θ2 . . . , θn)
The acceptance probability for a Metropolis-Hastings update as given in the
section above is:
α(θ, θ′) = min
{
1,
π(θ′)q(θ|θ′)
π(θ)q(θ′|θ)
}
= min
{
1,
π(θt+11 , θ
t
2 . . . , θ
t
n)π1(θ
t
1|θt2 . . . , θtn)
π(θt1, θ
t
2 . . . , θ
t
n)π1(θ
t+1
1 |θt2 . . . , θtn)
}
= min
{
1,
π(θt+11 , θ
t
2 . . . , θ
t
n)π(θ
t
1, θ
t
2 . . . , θ
t
n)π(θ
t
2 . . . , θ
t
n)
π(θt1, θ
t
2 . . . , θ
t
n)π(θ
t+1
1 , θ
t
2 . . . , θ
t
n)π(θ
t
2 . . . , θ
t
n)
}
= 1.
It is possible to use a mixture of updating methods for the parameter val-
ues within the same iteration of the MCMC - Gibbs sampling for some of the
parameters and Metropolis-Hastings for the remainder.
Proposal Distributions
Metropolis-Hastings samplers require a proposal distribution which is used to
simulate the next parameter value. A proposal distribution is usually depen-
dent on the immediately previous value of the parameter, but independent of
other previous values to ensure the Markov property holds.
A popular choice of proposal distribution is the random walk proposal. A
common example is the normal distribution centered at the current parameter
value. The proposal variance is arbitrary in this distribution and the value
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assigned to it affects the simulation. If the variance is too small then lots of
small updates will be made to the parameter but it may take a long time to
reach all areas of the sample space. If the variance is too large this will result
in many proposals being rejected and the chain will not move very often at all.
In both cases this means good estimates of the parameter will take a long time
to achieve. See figure 1.6 for examples of plots of parameter histories when the
proposal distributions have either too small or too large variance. We wish to
strike a happy medium between these two cases where the proposed points are
accepted around 40-60% of the time.
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Figure 1.6: TOP: plot of a parameter history where the variance of the proposal
distribution is too small. Note that nearly all proposals are accepted.
BOTTOM: plot of a parameter history where the variance of the proposal
distribution is too large. Note that only a few proposals are accepted.
Symmetric proposal distributions simplify the computation in parameter
updates using the Metropolis-Hastings algorithm. The ratio to be calculated
in a Metropolis-Hastings update is
α(θ(t), φ) = min
{
1,
π(φ|y)q(θ(t)|φ)
π(θ(t)|y)q(φ|θ(t))
}
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but if, for example, the proposal distribution is Gaussian centred around the
current estimate, the ratio of proposal distributions is
q(θ(t)|φ)
q(φ|θ(t)) =
N(φ, σ2)
N(θ(t), σ2)
=
1√
2πσ2
e
−
1
2σ2
(θ(t) − φ)2
1√
2πσ2
e
−
1
2σ2
(φ− θ(t))2
= 1
thus simplifying the Metropolis-Hastings update ratio to
α(θ(t), φ) = min
{
1,
π(φ|y)
π(θ(t)|y)
}
Hence, the chain will remain in states with higher posterior probability more
often while states with lower posterior probability are visited less often. This
special case of the Metropolis-Hastings algorithm was the original case pro-
posed by Metropolis et al. (1953).
Convergence, Burn In and Thinning
MCMC has enabled the application of Bayesian methods to many situations in
different branches of study. However, to ensure that the results from MCMC
algorithms are reliable two important issues need to be taken into considera-
tion - burn in and thinning.
For a Markov chain whose distribution (θ(t)) converges as t → ∞ there is
a sufficiently large t, such that the resulting (θ(t)) is an approximate obser-
vation from the posterior distribution π(θ|y). However, the speed at which
this happens, i.e. the rate of convergence of the chain, can vary greatly. The
burn in period of a chain consists of all the iterations up to iteration t and
these iterations are discarded from the analysis. From then on, the parameter
values obtained are sampled approximately from the posterior distribution of
interest provided the conditions of irreducibility, aperiodicity and reversibility
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are satisfied (see for example, Gilks et al., 1996).
The main problem comes in determining how large ‘t’ has to be. This is
generally monitored by the use of trace plots. Trace plots are plots of the his-
tory of the parameter values over many iterations and an example of a trace
plot where convergence has been reached is shown in figure 1.7.
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Figure 1.7: A trace plot of a model parameter. The dashed line shows roughly
where the burn in period ends. Iterations to the left of the line are discarded
as burn in, iterations to the right are used for analysis.
So after the burn in period we obtain, at each iteration, a sample from the
posterior distribution π(θ|y). However, the samples obtained are not usually
independent observations. To reduce the auto-correlation between observa-
tions we can thin the chain. This means that only one observation is kept for
analysis every k iterations where the value of k can be chosen by the experi-
menter. Thus approximate independent sampling from π(θ|y) can be achieved.
Also the amount of data created is reduced which aids the analysis.
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1.6 Multilevel Modelling
There are many real-life examples of multilevel structures. The most popular
example is that of an educational system with pupils within classes within
schools. We say that pupils are nested within classes which are nested within
schools. Goldstein and Spiegelhalter (1996) use multilevel modelling in this
educational setting.
In the proteomic setting, the m/z values are called level 1 units. This is
the lowest level of classification. The level 2 units are the spectra to which the
m/z values belong. The data structure for a general dataset can theoretically
contain any number of levels.
When data conform to such a multilevel structure it is important to take
account of this in the analysis otherwise the results obtained could be inac-
curate. For example, intensities at m/z values close to one another within
one spectrum are more likely to be similar than those from another spectrum.
This means they provide less information than if they were independent ob-
servations. It is important to know how this structure in the data will affect
the analysis. Before the development of multilevel modelling, the problems
of ignoring hierarchical structures were understood but they were difficult to
solve because general tools were not available. In order to see why multilevel
modelling is important we firstly review linear modelling.
1.6.1 Linear Modelling
Linear modelling is concerned with explaining the relationship between a single
response variable Y and one or more predictor variables X1, X2, . . . , Xp. A
linear model is written as
yi = x
T
i β + ei
= x1iβ1 + x2iβ2 + . . .+ xpiβp + ei , (i = 1, . . . , n) (1.14)
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In equation (1.14), β = (β1, . . . , βp)
T is a vector of unknown, fixed parame-
ters. The data consists of n observations each comprising a response yi and p
predictors xi. It is assumed that there exists only one random error term ei
for each observation and that these errors are iid N(0, σ2) where σ2 is unknown.
The simplest linear model is the null model and is written simply as
yi = β0 + ei , ei ∼ N(0, σ2).
In this model we are only finding the mean (β0) and the variance (σ
2) of the
sample. To improve the fit of the model we can include a continuous predictor
variable. This creates a linear regression model
yi = β0 + β1x1i + ei , ei ∼ N(0, σ2).
This fits a regression line relating Y to X. Other variables can also be added so
that the response variable Y is explained by more than one predictor variable.
Categorical predictors, where the values identify group membership, can be
included in a linear model by considering an Analysis of Variance (ANOVA)
model. Here the categorical predictor divides the data into J groups. The
ANOVA model is written as
yi = β0 +
J∑
k=1
dkiαk + ei , ei ∼ N(0, σ2)
where dki = 1 if k = i, and 0 otherwise. To make sure the model is identifiable
a constraint is placed on the α’s, e.g. α1 = 0. This model can be extended
to the Analysis of Covariance (ANCOVA) model by additionally including a
continuous predictor,
yij = β0 + β1x1ij +
J∑
k=1
dkijαk + eij , eij ∼ N(0, σ2) , α1 = 0
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with dkij defined as in the ANOVA model.
In all of the above examples of linear models the general form is
yij = x
T
ijβ + eij
and the only difference is in the definition of xij and β. For the ANCOVA
model xTij = (1, x1ij , d2ij, . . . , dJij) and β
T = (β0, β1, α2, . . . , αJ). Note that
d1ij and α1 are omitted since α1 = 0.
To estimate the values of the parameters in β we can use Least Squares
Estimation to obtain Maximum Likelihood Estimates. Writing the model in
matrix form gives the following:
y = Xβ + e , E(e) = 0 , E(eTe) = σ2 (1.15)
where y = (y1, y2, . . . , yn)
T , X = (xT1 ,x
T
2 , . . . ,x
T
n )
T , β = (β1, β2, . . . , βp)
T ,
e = (e1, e2, . . . , en)
T and e ∼ N(0, σ2I).
The least squares method estimates the parameters by minimising the sum
of the squared residuals
∑
i(yi − (Xβ)i)2 and it is easy to show that
βˆ = (XTX)−1XTy (1.16)
assuming X has full rank. Thus estimates can be obtained for the parameters
in a linear model simply by multiplying the correct matrices.
1.6.2 How Multilevel Modelling Differs from Linear
Modelling
In the proteomic setting previously mentioned there exist m/z values within
spectra. The modelling problem is how to model the intensities at each m/z
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value. Let yij be the intensity for m/z value i in spectrum j. A possible model
is
yij = β0 + uj + eij , uj ∼ N(0, σ2u) , eij ∼ N(0, σ2e) (1.17)
In this model β0 is the estimated average for the group, uj are the spectrum
effects (which have variance σ2u) and eij are them/z value residuals (which have
variance σ2e). We assume that the uj and the eij are independent and identi-
cally distributed (iid) and also that they are independent from each other.
In the ANOVA model the equivalent of the spectrum effects were the αj .
These parameters were considered to be fixed effects in the model and a con-
straint was required to fully identify the model. Conversely, in the multilevel
model in equation (1.17) the spectrum effects are treated as random effects that
come from a normal distribution. This model is called a variance components
model as the total variance in the response y is split into two parts - a vari-
ance between spectra σ2u and a variance between m/z values within spectra σ
2
e .
The next type of multilevel model is the random intercept model and is
related to the ANCOVA linear model described in the previous section. The
model is
yij = β0 + β1xij + uj + eij (1.18)
where uj ∼ N(0, σ2u) and eij ∼ N(0, σ2e). This will produce a different regres-
sion line for each of the spectra, although each will have the same slope as the
model assumes that the influence of the predictor variable x is the same for
each spectrum. To remove this assumption we can consider a random slopes
model. This is similar to a separate regression for each spectrum in linear mod-
elling, however, the results will not be exactly the same due to the random
effects assumption. In the random slopes model
yij = β0 + β1xij + u0j + u1jxij + eij (1.19)
where uj = (u0j, u1j) ∼ MVN(0,Ωu) and eij ∼ N(0, σ2e). The multivariate
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normal (MVN) distribution with a mean vector µ of dimension 1 × N , and
positive-definite, real, N × N covariance matrix Σ has probability density
function
fX(x1, . . . , xN) =
1
(2π)N/2 |Σ|1/2
exp
(
−1
2
(x− µ)⊤Σ−1(x− µ)
)
.
We now consider a general way of expressing all multilevel models with 2
levels.
1.6.3 The General Two-Level Model
All of the multilevel models in section 1.6.2 have had two levels - m/z value
and spectrum. The general two-level model is written thus:
yij = X
T
ijβ + Z
T
ijuj + eij (1.20)
with uj ∼ MVN(0,Ωu) and eij ∼ N(0, σ2e). This can be written in matrix
form as y = Xβ + Zu + e. Alternatively it can be written in multivariate
normal formulation as
y ∼ MVN(Xβ,V)
where V = ZΩuZ
T + σ2eI is a variance/covariance matrix of dimension N ×N
(in our case N is the number of spectra multiplied by the number of m/z val-
ues).
In a similar way to how the parameter estimates were obtained for lin-
ear models using least squares estimation, Generalised Least Squares (GLS,
Aitken, 1935) can be used in the multivariate case. We wish to obtain esti-
mates of β in the following equation of which the above multivariate normal
model is a special case:
y = Xβ + e , E(e) = 0 , E(eeT ) = V.
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The likelihood for the general two level model is
L(β,V;y) ∝ (2π)−N/2|V|−1/2 exp {−1
2
(y −Xβ)TV−1(y −Xβ)}
and thus the loglikelihood is
l(β,V;y) ∝ −1
2
log |V| − 1
2
(y −Xβ)TV−1(y −Xβ)
= −1
2
(
log |V|+ (y −Xβ)TV−1(y −Xβ)
)
The deviance of the model is defined as D = −2 × l(β,V;y) and is used to
compare models. The model with the lower deviance is considered a better
model.
It can be determined using the likelihood and GLS (e.g. Mardia, Kent and
Bibby, 1979) that the solution to the maximising problem is given by
βˆ = (XTV−1X)−1XTV−1y (1.21)
and the results in equation (1.16) can be obtained on substitution of V = σ2I.
The matrix V is the covariance matrix for all observations. It is block
diagonal (with each block representing one level 2 unit) and its elements depend
on the model being used. For the general two level model in equation (1.20)
the elements of V are:
• Cov(yij, yij′) = 0, (i 6= i′, j 6= j ′).
• Cov(yij, yi′j′) = ZTijΩuZi′j , (i 6= i′, j = j ′)
• Cov(yij, yi′j′) = ZTijΩuZij + σ2e , (i = i′, j = j ′)
where i indexes the level 1 unit and j indexes the level 2 unit.
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The use of block diagonal matrices is useful when using GLS to estimate
parameters as it involves inverting matrices. If V were not block diagonal
then inverting it would become difficult as its dimension increased. The block
diagonal structure means that each of the blocks can be inverted separately
and then combined.
1.6.4 The IGLS Algorithm
In the multilevel setting described in section 1.6.3, estimates need to be found
for the fixed effects parameters β and the variance parameters Ωu and σ
2
e .
If the two variances Ωu and σ
2
e were known then the covariance matrix V,
containing the variances and covariances of the random terms over all levels of
the data, can be calculated using GLS to be
β = (XTV−1X)−1XTV−1y (1.22)
Since it is unlikely that these variances will be known then they will need to
be estimated from the data using an iterative procedure. Iterative Generalised
Least Squares (IGLS) is an iterative algorithm developed by Goldstein (1986)
and is based on generalised least squares (GLS) estimation. The algorithm
will now be described.
Firstly note that, if A is an (m × n) matrix, with columns, A1, A2, ..., An,
each vectors of length m, then the vector of length mn obtained by stacking
the columns on top of one another is denoted,
vec(A) =


A1
A2
...
An

 .
Secondly, if A is a matrix of dimension (m × n), with individual entries, aij ,
i = 1, ..., m, j = 1, ..., n; and B is a (p× q) matrix then the Kronecker product
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of A and B is defined as,
A⊗ B =


a11B a12B . . . a1nB
a21B a22B . . . a2nB
...
...
. . .
...
am1B am2B . . . amnB

 ,
which is an (mp× nq) matrix.
The first step in the IGLS algorithm is to assume that you have a simple
linear model and obtain an initial estimate for β :
βˆ = (XTX)−1XTy
Next, define the vector of residuals. For the random intercept model de-
scribed in section 1.6.2 the residuals are y˜ij = yij − βˆ0 − xij βˆ1. We can then
combine these residuals into a vector Y˜ = {y˜ij} from which we can define
Y∗ = vec(Y˜Y˜T ). The matrix Y˜Y˜T has expected value V and so Y˜ allows us
to model the variances.
The elements of V for the random intercept model are σ2u+σ
2
e for elements
on the diagonal, σ2u for other elements within the blocks on the diagonal and
zero elsewhere. This gives the structure of Y∗ as
Y∗ =


y˜211
y˜221y˜
2
11
...
y˜2kn

 =


σ2u + σ
2
e
σ2u
...
σ2u + σ
2
e

+E = σ2u


1
1
...
1

+σ2e


1
0
...
1

+E = Z∗θ+E
(1.23)
for n level 2 units each with k level 1 units and where θ = [ σ2u σ
2
e ].
To update the estimates obtained earlier from assuming a simple linear
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model we then iterate between
θˆ = (Z∗
T
V∗
−1
Z∗)−1Z∗
T
V∗
−1
Y∗
and
βˆ = (XTV−1X)−1XTV−1y
and where V ∗ = V
⊗
V to get better estimates. Convergence occurs when
successive iterations give estimates within a certain tolerance value of each
other. Since IGLS is an extension of GLS estimation the assumption of nor-
mality is not required. If the assumption holds, however, then MLE estimates
for the parameters are obtained.
1.6.5 Hypothesis Testing
The IGLS algorithm described in the last section gives estimates of both the
fixed and variance parameters in a multilevel model along with their standard
errors. To identify when particular parameters are important in the model we
can carry out hypothesis tests to show statistical significance.
In hypothesis testing a question of interest is simplified into two mutually
exclusive hypotheses between which there is a choice; the null hypothesis, H0,
and the alternative hypothesis, H1. The null hypothesis normally represents
no difference, for example, in the melanoma dataset a possible null hypothesis
is that at an m/z value of 8,000 Daltons there is no difference in the intensities
between stage I and stage IV. The alternative hypothesis is normally a state-
ment of what the test is set up to establish, for example, that at an m/z value
of 8,000 Daltons the relative intensity in stage I is lower than in stage IV. The
appropriate test statistic is calculated and compared with the critical value (at
a particular significance level) to determine which hypothesis is accepted.
For the fixed effects in a multilevel model we are normally interested in
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whether the parameter estimate is significantly different from zero. We have
obtained the parameter estimate βˆ1 and its estimated standard error SˆE(βˆ1)
and thus we could carry out a t-test (Student, 1908). However, since the size
of the datasets normally considered for multilevel modelling are so large we
can obtain an approximate result using a Z-test. In this case the value of the
statistic Z is:
Z =
βˆ1
SˆE(βˆ1)
which is distributed as N(0,1) under H0 : β1 = 0. Thus at the 5% level we
reject the null hypothesis H0 : β1 = 0 in favour of the alternative hypothesis
HA : β1 6= 0 when |Z| > 1.96
It is also important to consider which model is the best for the data avail-
able. The best model is easy to identify when the models are nested. Two
models, A and B, are said to be nested if the parameters in model A are a
proper subset of the parameters of model B. In this case the null hypothe-
sis is H0 : θ = 0 for all θ parameters in the complex model which are not
in the simpler model. We calculate the deviance of each model, Dev(A) and
Dev(B), and then the approximate test statistic under the null hypothesis is
D = (Dev(A)−Dev(B)) ∼ χ2p where p is the number of extra parameters in
the more complex model (for large samples).
Another method which is used to compare models is the Akaike Information
Criterion (AIC, Akaike, 1974). This method more directly takes into account
the number of extra parameters in a model. The AIC statistic λA for a model
A is calculated by λA = Dev(A)+ 2p where p is the numbers of parameters in
the model. A lower value of λA indicates a more preferable model. The AIC
criterion does not require the use of nested models.
A similar criterion to AIC is the Bayesian Information Criterion (BIC,
Schwartz, 1978). The BIC statistic λB for a model B is calculated by λB =
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Dev(B)+plog(n) where p is the number of parameters in the model and n is the
number of datapoints. For the datasets considered in this thesis the values of
n will be 2,009,088 and 2,859,955 for the breast cancer and melanoma datasets
respectively and thus the value of log(n) for both datasets is around 15 as
compared with 2 in the AIC statistic. This means that the introduction of
more parameters is punished more harshly when using the BIC as compared
with the AIC. Again, a lower value of λB indicates a more preferable model
and nested models are not required.
1.6.6 False Discovery Rate
If a large number of simultaneous (independent) hypothesis tests are conducted
without multiple comparison adjustment then we would expect 100α% of the
tests to be significant even if H0 is true at the 100α% significance level.
Benjamini and Hochberg (1995) suggested a method to reduce the number
of incorrectly classified significant results. Their method selects significant
results by considering their p-values. When testing m hypotheses there are
four categories that the result can fall into as shown in table 1.4.
declared not significant declared significant total
true null hypotheses U T n
false null hypotheses N S m-n
total m-R R m
Table 1.4: The 4 ways of classifying observations
The proportion of errors committed by falsely rejecting null hypotheses is
Q = T/(T + S). The false discovery rate (FDR) is defined to be the expec-
tation of Q. The Benjamini and Hochberg (1995) algorithm is described below:
• Consider m null hypotheses H1, ..., Hm and their respective p-values
p1, ..., pm.
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• Arrange the p-values in ascending order so that p(1) ≤ p(2) ≤ . . . ≤ p(m).
• Choose a value q∗ to be the FDR.
• Compare each p(i) to iq∗m . Let k be the smallest i such that p(i) > iq
∗
m
.
• Reject all the null hypotheses with p-values p(1), ..., p(k−1) and accept all
the others.
Benjamini and Hochberg (2000) refined this algorithm. The new algorithm
is similar to the previous one in that it uses the p-values to select significant
results, however, it uses the rate of change in the p-values to decide where the
cut-off point should be instead of just the actual p-values themselves. Using
either of these two algorithms results in the threshold for significance being
increased and thus fewer results are deemed significant.
In this thesis we use the original 1995 method to identify significance when
testing multiple hypotheses in chapters 3 and 4.
47
Chapter 2
Classification of Proteomic
Spectra using a Deterministic
Peak Finding Algorithm
2.1 Introduction
In section 1.4 an overview of the two main data reduction methods and the
different methods of classification were presented. This chapter will consider
the use of these methods to classify new spectra once the peaks in the data
have been obtained. After a short motivation, the algorithm for identifying
the peaks is described in section 2.3 and the results obtained are described in
sections 2.4 and 2.5.
2.2 Motivation
When searching for biomarkers for disease in proteomic data the aim is to find
a small subset of the available m/z values which correctly classify disease state.
It would also be beneficial if these biomarkers had some biological relevance.
Preliminary work carried out using principal components analysis (PCA)
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has enabled mostly correct classification of the spectra in both the breast can-
cer and melanoma datasets. However, although PCA is successful at reducing
the dimension of the datasets, subsequent classification has been based on the
PCs obtained. These PCs are constructed using all of the data and thus are
not very biologically interpretable. Results obtained from this preliminary
analysis are presented with the main results of this chapter in sections 2.4 and
2.5.
In figure 2.1 it can be seen that a mass spectrum consists of a series of
distinct peaks. Each peak is centred around a particular m/z value and has
a height which can differ across spectra. This height represents abundance of
molecules - a larger peak implies a larger number of molecules with that m/z
value were identified in the sample. To classify spectra into groups we can use
this differing peak height information.
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Figure 2.1: Example showing the presence of distinct peaks in a small section
of a mass spectrum.
A method is now introduced by which spectra can be classified according to
the peak locations and heights. This method provides much more interpretable
reasons for classifications into particular groups.
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2.3 The Peak Finding Method
Assume we have n spectra with k observations (m/z values) in each. Let Yij
be the observed intensity at the ith m/z value in the jth spectrum. The aim is
to model the peaks in the dataset ensuring common peak locations across all
the spectra in order to aid the interpretability of the results.
We now outline a method for peak finding. To find the location of the first
peak, find a location i1 such that i1 = argmaxi
∑n
j=1 Yij. This is equivalent
to finding the largest peak in the mean spectrum. Place a Gaussian kernel of
the form c1jN(µ1, σ
2
1) = c1jf1 at this location. As suggested by the chemistry
(e.g. Hortin, 2006), we model σi to be proportional to µi, the peak location,
remembering that the constant of proportionality ξ still needs to be chosen.
The scaling parameter c1j then needs to be calculated for each spectrum j in
order that the height of the fitted peak matches the height of the data at that
point. In order to find the location of subsequent peaks, first form
Xij = Yij −
P∑
p=1
cpjfp(i)
where P is the number of peaks already fitted. This effectively ‘subtracts’
the peaks already accounted for in the method. Then find an ij such that
ij = argmaxi
∑n
j=1Xij , set µj = ij and find the scaling parameters as before.
Note that as we are only considering positive peak heights it is simpler to sum
the Xij instead of their squares. Repeat this algorithm until the desired num-
ber of peaks is fitted. We thus have a two-step procedure - we iteratively find
the best position to fit a peak (conditional on the presence of existing peaks)
and then calculate the required scaling parameters for the height of this peak
in order that the fitted function matches the data exactly at the peak location.
We simplify matters in this model by assuming that ξ is a known constant,
although a suitable value of ξ can be determined quite easily by trial and
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error. The algorithm takes of the order of seconds to find the peaks and so
many values of ξ could be tested to find which appears to best match the data.
However, in this thesis ξ is chosen by a least squares method minimising the
residual error.
There is a potential problem with this method as it stands concerning peaks
that overlap significantly. If all the peaks are far apart from each other then
the small area in the tails of the distributions should not affect the heights
of the other peaks significantly. However, if the peaks are close together then
height contributions from the other peaks could affect how well the modelled
peak heights actually fit the data. For an example when just two peaks are
being fitted see figure 2.2.
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Figure 2.2: Example showing a peak arrangement with extra contribution to
peak heights after a second peak has been fitted.
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In figure 2.2, the peak around m/z value 7,000 is fitted according to the
above algorithm. The green line shows the resulting fitted heights at each
m/z value when the second peak is fitted. It is seen that there is an extra
contribution to the peak height at, for example, point µ1 = 7, 000. Also the
previously correctly fitted peak at m/z = 7, 000 contributes some extra height
to peak 2 at, for example, point µ2 = 6, 900. This occurs at all points where
the distributions of the fitted peaks overlap and could result in substantially
incorrect fitted heights. This phenomenon gets worse the larger the number of
fitted peaks. In order to eliminate this problem we need to consider all peaks
simultaneously, not separately as suggested above. In fitting the second peak
we wish to match the heights of both peak 1 and peak 2. This can be achieved
by solving the following two simultaneous equations in the two unknowns c1j
and c2j:
c1jf1(i1) + c2jf2(i1) = Yi1,j
c1jf1(i2) + c2jf2(i2) = Yi2,j , (2.1)
where j is the spectrum number and ip is the m/z value location of the p
th
peak. This procedure is repeated every time a new peak is added, each time
solving p equations in p unknowns for each spectrum. This system of equations
can be solved in matrix notation by C = F−1Y where C = [c1j . . . cpj],
Y = [yi1,j . . . yip,j] and
F =


f1(i1) f2(i1) . . . fp(i1)
f1(i2) f2(i2) . . . fp(i2)
...
...
. . .
...
f1(ip) f2(ip) . . . fp(ip)

 .
The red line in figure 2.2 shows the fitted heights at each m/z value when
this approach has been used. The heights obtained are closer to the data than
previously.
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The algorithm can be adapted to either end after a specified number of
peaks have been fitted or to continue until the Xij ’s are all less than a certain
tolerance value.
In summary, the peak finding algorithm is as follows
1. For each m/z value, add up the intensities for each spectrum in the
dataset at that m/z value to obtain a single overall spectrum.
2. Find the m/z value location of the largest peak in the overall spectrum.
3. For each spectrum, place a Gaussian kernel at this m/z value with stan-
dard deviation proportional to its mean.
4. (a) If you are fitting the first peak: For each spectrum, calculate the
scaling parameter which will match the height of the Gaussian ker-
nel to the data at that m/z value.
(b) If you are fitting subsequent peaks: For each spectrum, calculate the
scaling parameters for all peaks currently identified by the algorithm
by solving simultaneous equations.
5. For each spectrum, subtract the modelled peak(s) from the original data.
6. As in step 1, sum the intensities in this subtracted dataset at each m/z
value to obtain a new overall spectrum
7. Repeat steps 2 to 6 until a specified number of peaks have been fitted.
It should be noted that as we add the kth peak the algorithm requires
the inversion of n, k × k matrices. This results in fast calculations for small
(< 50) numbers of peaks but results for a larger number of peaks are more
computationally expensive. The algorithm is now applied to the breast cancer
and melanoma datasets.
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2.4 Applying the Algorithm to the Breast
Cancer Dataset
2.4.1 Goodness of Fit
The algorithm was firstly applied to the whole dataset in order to assess if the
fitted curves were a suitable approximation to the real data. Figure 2.3 shows
the actual spectra and the modelled peaks based on the locations obtained
using the peak finding algorithm for a small section of the data in the adcon
group between 6,800 Da and 8,400 Da. One hundred and fifty peaks were used
for the whole dataset and 8 of them were in this range. Peak locations were
common across all spectra in the dataset. The black lines are the modelled
peaks and the red lines are the cell line data which are reflected in the x axis.
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Figure 2.3: The peaks selected in the adcon group using the deterministic peak
finding method and fitting 8 peaks. Red lines show the original data (reflected
in the x-axis) and black lines show the fitted values using the peak finding
algorithm.
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It is clear that the algorithm is picking out the peak locations well. The
differences in height for different spectra are apparent and are a good match
to the original data. To analyse how well the model fits the data we now
consider residual plots. These show the differences between the data and the
fitted model and are presented in figure 2.4 for the adcon group over the same
range of m/z values as previously.
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Figure 2.4: The residuals obtained for the adcon group by subtracting the
model from the data.
Overall the residuals seem to be fairly small on day 1, however, there are
some patterns evident in figure 2.4. There are two main reasons for these
patterns. Firstly some of the peaks have too large a variance as can be seen
at m/z values around 7,000 and 8,100 Da in figure 2.5. For the single peak
at 8,100 Da the large variance results in a much wider peak than is actually
present. Around 7,000 Da the presence of two close peaks each with too large
a variance results in the trough between them being incorrectly modelled. Sec-
ondly, the prerequisite that the peaks have to have common locations across
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Figure 2.5: An example spectrum over the range 6,800-8,400 Da and the fitted
model obtained from the peak finding algorithm. The red line shows one
spectrum from the breast cancer dataset and the black line shows the fitted
model.
all spectra means that, in some cases, the model is not matching to the correct
peak height for that particular spectrum. For example, at 7,900 Da the model
is matching to a datapoint on the slope of the peak.
Peak variances are linked to the m/z value at which they occur - the stan-
dard deviation is proportional to the location. So to ensure the peaks have
smaller variances the constant of proportionality, ξ, can be made smaller. This,
however, will have effects on all of the other peaks and may create less well
fitting peaks somewhere else.
2.4.2 Classification
The complete dataset (144 spectra - 24 in each of 6 groups) was split into
training and test sets with 16 spectra from each of the 6 groups comprising
the training set - 96 spectra in total. The peak finding procedure detailed
in the previous section was run on the training set using ξ = 0.000039 for
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the value of the proportionality constant. This value was obtained from the
MCMC analysis to be presented in chapter 3. A selection of ξ values were
tested around the value 0.000039 and the resulting peak locations did not
change substantially. The peak locations obtained were used to fit the model
to the test data and then various classification methods were employed to pre-
dict the group memberships of the test spectra. This algorithm was repeated
1,000 times.
Three different sets of methods for classifying the test data were used -
support vector machines (SVM), discriminant analysis (linear and quadratic,
LDA and QDA) and K-nearest-neighbour (KNN, K = 1, 5, 10 or 20) all of
which are described in more detail in section 1.4.2. The peak finding algorithm
fitted the peaks in order of size and, since it is not necessarily true that the
larger peaks are the better classifiers, the peak locations obtained needed to
be reordered. The most ‘dataset independent’ way of doing this was to order
the peaks by best classification of the training data using the same method.
For each method of classification the best 50 classifiers were used to classify
the data instead of the full 150 as this greatly reduced the computation time.
Six of the methods of classification thus required the peaks to be reordered.
It is impossible to order the peaks by best classification of the training data
when using 1-nearest-neighbour as the training set is always perfectly classified.
The classification results are summarised in table 2.1 which shows the method
used to classify, the maximum percentage of correct classifications with a 4 s.d.
range and the number of peaks that had to be included to reach this maximum
percentage. PCA and ICA were also carried out on the complete spectra before
classification. As previously the PCs/ICs were ordered by best classification
of the training data before their use to classify a test set. A summary of the
results of this analysis is shown in table 2.2. The complete classification curves
for all analyses are shown in figures 2.6 and 2.7.
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method correctly classified ± 2s.d. no of peaks
LDA 84% (78,90) 28
SVM 75% (69,81) 50
KNN (K=5) 74% (67,81) 22
KNN (K=10) 72% (64,80) 19
KNN (K=1) 72% (65,79) 44
QDA 70% (62,78) 6
KNN (K=20) 70% (62,78) 21
Table 2.1: Percentage of correct classifications obtained using the peak finding
algorithm and 7 different classification methods.
method correctly classified ± 2s.d. no of pcs/ics
PCA+LDA 89% (84,94) 50
PCA+SVM 83% (78,88) 30
PCA+QDA 76% (70,82) 9
PCA+KNN (K=1) 71% (64,77) 50
PCA+KNN (K=5) 65% (58,72) 50
PCA+KNN (K=10) 62% (54,70) 50
PCA+KNN (K=20) 59% (51,67) 50
ICA+LDA 90% (85,95) 50
ICA+SVM 84% (79,89) 30
ICA+KNN (K=5) 75% (68,82) 25
ICA+KNN (K=10) 74% (68,80) 19
ICA+KNN (K=1) 74% (68,80) 50
ICA+KNN (K=20) 72% (64,78) 20
ICA+QDA 41% (32,50) 10
Table 2.2: Percentage of correct classifications obtained using PCA/ICA on
the complete spectra and 7 different classification methods.
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Figure 2.6: Classification curves using LDA, QDA, SVM and KNN (K = 1)
combined with the fitted peak heights, and the PCs and ICs obtained from
the entire dataset. Black lines show the mean and red lines ± 2 s.d.
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Figure 2.7: Classification curves using KNN (K = 5, 10, 20) combined with
the fitted peak heights, and the PCs and ICs obtained from the entire dataset.
Black lines show the mean and red lines ± 2 s.d.
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From tables 2.1 and 2.2 it can be seen that LDA and SVM appear to be
the better classifiers achieving correct classification rates of 84%-90% and 75%-
84% respectively. Note that although the PCA/ICA classification rates were
calculated using the complete spectra and are thus relatively high, the correct
classification rates for the peak finding method are not much lower despite the
reduction in the amount of data used. Also the PCA classifications require
around 50 PCs to obtain their maximum correct classification rates, whilst the
peak finding algorithm often requires fewer peaks to reach its maximum.
Using KNN on the PCs results in a lower number of correct classifications
than using KNN on the peaks for all 4 values of K considered. Using KNN
on the ICs results in a similar classification rate to the peak finding results.
QDA does particularly badly when combined with ICA resulting in only 41%
correct classifications.
Tables 2.3 and 2.4 show the peak locations most often identified as the best
classifiers of the training data, when using LDA and SVM respectively, over
all 1,000 iterations. The m/z values of 8,104 Da, 7,453 Da and 4,393 Da are
the best first classifiers of the training data using both classification methods
collectively being chosen first 96.6% and 90.1% of the time for LDA and SVM
respectively. Note that only classifiers with totals above 150 are shown.
In figures 2.8 to 2.10 plots of the data are shown around the three m/z
values in tables 2.3 and 2.4 which are selected most often as the first best
classifier. It is clear why these locations were picked as the best classifiers of
the data as the differences in height between the groups are so large. For the
peak in figure 2.8 at an m/z value of 8,104 Da the distinction between classes
is quite clear. The adcon and adtax groups have the highest peaks, the tdcon
and tdtax groups have middle sized peaks and the mccon and mctax groups
have flatter peaks.
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order of best classification
of training data
peak location 1st 2nd 3rd 4th 5th 6th total
8,104 664 129 8 10 12 9 832
7,453 180 384 14 12 9 11 610
11,701 0 1 265 97 47 35 445
5,416 0 89 79 59 93 73 393
11,133 0 9 104 129 64 48 354
4,393 122 6 53 36 61 41 319
10,231 7 47 34 65 50 43 246
4,345 0 70 43 42 28 37 220
4,881 18 32 42 46 26 27 191
13,835 0 0 16 45 49 72 182
3,050 0 88 7 29 19 10 153
total 991 855 665 570 458 406
Table 2.3: Peak locations which best classify the training data using LDA.
order of best classification
of training data
peak location 1st 2nd 3rd 4th 5th 6th total
4,393 243 83 209 66 47 38 686
8,104 390 112 71 27 24 17 641
4,345 9 267 143 87 62 38 606
5,416 0 102 203 59 44 21 429
4,881 59 150 52 25 44 52 382
7,453 268 34 14 16 19 13 364
2,180 0 0 8 67 95 66 236
10,231 5 62 22 27 35 28 179
5,707 0 27 27 38 45 38 175
5,366 0 25 27 60 23 21 156
total 974 862 776 472 438 331
Table 2.4: Peak locations which best classify the training data using SVM.
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Figure 2.8: Plot of the data around m/z value 8,104 separated by group.
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Figure 2.9: Plot of the data around m/z value 7,453 separated by group.
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Figure 2.10: Plot of the data around m/z value 4,393 separated by group.
The peak in figure 2.9 at an m/z value of 7,453 Da is the next best classi-
fier. For this peak we can see that the heights in the adcon and adtax groups
are much higher than the other four groups. For both the peak at 8,104 Da
and the peak at 7,453 Da the heights for the control spectra are larger than
those for the respective Taxol treated spectra. This suggests that the Taxol
treatment affects a cell by reducing the number of molecules at these m/z val-
ues. For the peak in figure 2.10 at an m/z value of 4,393 Da the opposite is
true. The peak heights are higher in the treated spectra than in the controls.
The largest peaks at this m/z value are to be found in the mccon and mctax
spectra. The heights in the other four groups are comparable in size.
Tables 2.5 to 2.6 show misclassification tables based on 1,000 simulations
for the LDA and SVM classification methods at the optimum number of peak
locations (indicated in column 4 of table 2.1). It appears that it is relatively
easy to discriminate between the three different types of cell-line but it is much
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harder to differentiate between Taxol-treated or non-Taxol-treated. The latter
is the more important comparison for the physician.
classified as
adcon adtax tdcon tdtax mccon mctax
tr
u
e
gr
ou
p
adcon 79.2 15.3 0.1 0 5.2 0.3
adtax 10.5 85.8 0 0 3.4 0.3
tdcon 0 0.8 88.9 9.7 0.2 0.4
tdtax 0 0.1 10.0 87.7 0.4 1.8
mccon 0.2 0.1 0 0 88.9 10.8
mctax 0.3 0.1 0 0 17.2 82.4
Table 2.5: Percentage of correct classifications using LDA on the fitted peak
heights at 30 locations.
classified as
adcon adtax tdcon tdtax mccon mctax
tr
u
e
gr
ou
p
adcon 67.4 24.6 0 0 8.0 0
adtax 19.6 75.7 0 0 4.8 0
tdcon 0.1 0 94.3 2.9 2.6 0
tdtax 4.4 0 12.0 80.7 2.8 0.2
mccon 2.1 0.7 0 0 80.7 16.5
mctax 2.0 2.2 0 0 26.2 69.6
Table 2.6: Percentage of correct classifications using SVM on the fitted peak
heights at 50 locations.
There are an appreciable amount of adcon and adtax spectra misclassified
into the mccon group. This is not wholly unexpected as ADR/MCF-7 cell-lines
are treated versions of MCF-7 cell-lines and thus some similarities should be
expected.
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2.5 Applying the Algorithm to the Melanoma
Dataset
2.5.1 Goodness of Fit
To check if the algorithm was giving a suitable approximation to the data the
whole dataset was modelled and a fitted curve for each spectrum obtained
using the deterministic peak finding algorithm. In figure 2.11 we see a small
subset of the data, between 6,800 Da and 8,400 Da which shows sections from
six actual spectra and the modelled peaks based on the locations obtained
using the peak finding algorithm. One hundred and fifty peaks were used for
the whole dataset and 10 of them were in this range. The black lines are the
modelled peaks and the red lines are the cell line data which are reflected in
the x axis.
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Figure 2.11: The peaks selected in 6 spectra from the melanoma dataset using
the deterministic peak finding method and fitting 10 peaks.
The peaks in the data are identified well by the algorithm and height dif-
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ferences between different spectra are apparent which results in a good match
to the original data. We now consider residual plots to assess how well the
model fits the data. Residual plots for the same six spectra shown in figure
2.11 are presented in figure 2.12.
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Figure 2.12: The residuals obtained for the 6 spectra in figure 2.11 by sub-
tracting the model from the data.
In general the residuals are fairly small, however, there are three areas in
figure 2.12 where the residuals show patterns. As discussed in section 2.4.1
for the breast cancer dataset two possible reasons are peaks having too large
a variance or modelled peaks not having exactly the same location as the data
due to the common location restriction. These reasons explain the residual
patterns around the m/z value 6,500 Da. In addition we note that for the
melanoma dataset many of the peaks appear to have a non-Gaussian shape.
This results in modelled peaks with broader slopes than the data on one side
of the peak and thus the residuals show this pattern. From figure 2.13 we can
see that the modelled peak at an m/z value of 7,800 Da gives rise to this type
of residual pattern. Some of these problems will be addressed in chapter 3 by
using multiple peaks.
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Figure 2.13: An example spectrum over the range 6,000-8,500 Da and the fitted
model from the peak finding algorithm. The red line shows one spectrum from
the melanoma dataset and the black line shows the fitted model.
2.5.2 Classification
All of the spectra in the dataset (205 spectra - 101 in stage I and 104 in
stage IV) were designated ‘training’ or ‘test’ with 68 spectra from each of the
stages comprising the training set. Using the peak finding algorithm with
ξ = 0.000020, obtained from the MCMC analysis of this dataset to be pre-
sented in chapter 3, the training spectra were modelled. The peak locations
obtained were used to fit the model to the test data and then the various clas-
sification methods used previously were used to predict the stages of the test
spectra. The peak locations were reordered according to best classification
of the training data and, for LDA/QDA, by the absolute t-statistic at each
peak. The classification results from 1,000 repetitions of this algorithm are
summarised in table 2.7. PCA and ICA were also carried out on the complete
spectra before classification. As previously the PCs/ICs were ordered by best
classification of the training data before using the best 50 to classify the test
data. A summary of the results of the PCA/ICA analyses are shown in table
2.8. The complete classification curves for all analyses are shown in figures
2.14 and 2.15.
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method correctly classified ± 2s.d. no of peaks
t-test & LDA 85% (80,90) 12
SVM 83% (78,88) 48
bestclass & LDA 81% (76,86) 26
KNN (K=20) 81% (76,86) 28
t-test & QDA 80% (75,85) 8
KNN (K=10) 80% (75,85) 23
KNN (K=5) 80% (75,85) 31
bestclass & QDA 78% (74,82) 3
KNN (K=1) 75% (70,80) 50
Table 2.7: Percentage of correct classifications obtained using the peak finding
algorithm and 7 different classification methods.
method correctly classified ± 2s.d. no of pcs/ics
PCA+LDA 86% (82,90) 48
PCA+SVM 85% (80,90) 50
PCA+QDA 81% (75,87) 28
PCA+KNN (K=1) 76% (70,82) 50
PCA+KNN (K=20) 76% (70,82) 50
PCA+KNN (K=10) 74% (68,80) 50
PCA+KNN (K=5) 65% (55,75) 50
ICA+QDA 89% (80,98) 28
ICA+LDA 85% (80,90) 30
ICA+SVM 82% (76,88) 30
ICA+KNN (K=1) 60% (38,82) 1
ICA+KNN (K=5) 60% (38,82) 5
ICA+KNN (K=10) 60% (41,79) 2
ICA+KNN (K=20) 60% (41,79) 2
Table 2.8: Percentage of correct classifications obtained using PCA/ICA on
the complete spectra and 7 different classification methods.
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Figure 2.14: Classification curves using LDA, QDA and SVM combined with
the fitted peak heights, and the PCs and ICs obtained from the entire dataset.
Black lines show the mean and red lines ± 2 s.d.
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Figure 2.15: Classification curves using KNN (K = 1, 5, 10, 20) combined with
the fitted peak heights, and the PCs and ICs obtained from the entire dataset.
Black lines show the mean and red lines ± 2 s.d.
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LDA and SVM are shown to be good classifiers in tables 2.7 and 2.8 with
correct classification rates of 81%-86% and 82%-85% respectively. Note that,
similarly to the breast cancer dataset, the reduction in data used for the peak
finding method as compared with the complete spectra does not result in much
lower correct classification rates. Again the PCA classifications require around
50 PCs to obtain their maximum correct classification rates whereas the peak
finding algorithm often requires fewer peaks to reach its maximum. When
the same data were analysed by Mian et al. (2005) the data were split into
training, test and blind sets and classification was carried out using artificial
neural networks. The correct classification rate using these methods was 88%.
Using KNN on the ICs results in a much lower number of correct classi-
fications than any of the other methods with the average maximum correct
classification being 60%. However, the standard deviations in each of the IC
+ KNN cases are large. Not only does this give unreliable results but also
puts the lower confidence limit below 50% - suggesting results worse than the
value expected by chance. For the case K = 1 the entire classification curve
except for the first point is below the 50% level. ICA combined with QDA
also results in a large standard deviation. Neither of these methods should be
used to obtain reliable information about classifications.
Considering the results over all 1,000 iterations, the peak locations identi-
fied most often as the best classifiers of the training data are shown in tables
2.9 and 2.10 for the LDA and SVM classification methods. The best first
classifiers of the data occur at m/z values of 3,885 Da, 28,160 Da, 3,316 Da
and 2,227 Da using both LDA and SVM. They are collectively chosen first
99.5% and 99.2% of the time respectively. The three m/z values which are
selected most often as the first best classifier in tables 2.9 and 2.10 are plotted
in figures 2.16 to 2.18. In all three cases the average heights of the peaks in
stage I appears to be higher than those in stage IV.
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order of best classification
of training data
peak location 1st 2nd 3rd 4th 5th 6th total
3,885 917 51 1 0 1 1 971
28,160 60 153 43 24 13 17 310
8,154 0 2 9 51 69 62 193
2,040 0 108 22 21 15 23 189
7,978 0 4 23 41 62 46 176
3,316 12 22 82 24 17 16 173
8,949 0 3 12 48 52 50 165
8,820 0 108 25 15 7 8 163
2,771 0 69 54 17 16 5 161
2,227 6 67 37 19 17 15 161
7,777 0 2 31 28 49 50 160
2,495 2 92 30 11 7 9 151
total 997 681 369 299 325 302
Table 2.9: Peak locations which best classify the training data using LDA.
order of best classification
of training data
peak location 1st 2nd 3rd 4th 5th 6th total
3,885 916 25 5 2 3 0 951
2,040 0 104 59 68 54 44 329
28,160 29 85 58 41 30 34 277
2,771 0 175 43 19 10 19 266
2,359 0 17 46 59 47 48 217
3,316 14 45 53 35 30 20 197
8,949 0 1 37 48 63 40 189
2,227 33 57 43 16 15 15 179
2,269 0 61 42 35 17 22 177
2,495 0 86 40 18 14 7 165
2,540 0 24 20 33 29 23 129
9,460 0 17 36 29 13 17 112
total 992 697 482 403 325 289
Table 2.10: Peak locations which best classify the training data using SVM.
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Figure 2.16: Plot of the data around m/z value 3,885 separated by stage.
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Figure 2.17: Plot of the data around m/z value 28,160 separated by stage.
74
2.5 Applying the Algorithm to the Melanoma Dataset
3250 3300 3350 3400
0
2
4
6
8
10
stage I
mz value
re
la
tiv
e 
in
te
ns
ity
3250 3300 3350 3400
0
2
4
6
8
10
stage IV
mz value
re
la
tiv
e 
in
te
ns
ity
Figure 2.18: Plot of the data around m/z value 3,316 separated by stage.
A little further analysis shows why these three peaks are good classifiers. If
we consider the relative intensities for all spectra at one peak location we can
identify a dividing point at a particular relative intensity which results in the
majority of stage I spectra having lower (higher) intensities and the majority
of stage IV spectra having higher (lower) intensities.
For the peak in figure 2.16 at an m/z value of 3,885 Da, a dividing point
is located at a relative intensity of 4. At this point 75% of the stage I spectra
have higher intensities and 88% of the stage IV spectra have lower intensities.
For the peak in figure 2.17 at an m/z value of 28,160 Da, the dividing point
is at a relative intensity of 1.4. Then 73% of the stage I spectra have higher
intensities and 68% of the stage IV spectra have lower intensities. Lastly for
the peak in figure 2.18 at an m/z value of 3,316 Da, a dividing point is located
at a relative intensity of 3.1. At this point 70% of the stage I spectra have
higher intensities and 80% of the stage IV spectra have lower intensities.
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Tables 2.11 to 2.12 show misclassification tables for the LDA and SVM
classification methods at the optimum number of peak locations (indicated in
column 4 of table 2.7). The results for the two methods are similar although
the percentage of correct stage I classifications is slightly higher when using
SVM. To obtain this 4.2% increase, however, requires the use of nearly twice
as many peak locations.
classified as
stage 1 stage 4
tr
u
e stage 1 76.1 23.9
stage 4 14.6 85.4
Table 2.11: Percentage of correct classifications using LDA on the fitted peak
heights at 26 locations.
classified as
stage 1 stage 4
tr
u
e stage 1 80.3 19.7
stage 4 14.3 85.7
Table 2.12: Percentage of correct classifications using SVM on the fitted peak
heights at 48 locations.
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2.6 Summary
In this chapter we have developed a deterministic peak finding algorithm and
have shown how it can be used to successfully model mass spectrometry data.
Also it has been shown how we can use the models obtained to classify new
spectra. The results were obtained using C++ and the R programming lan-
guage.
The algorithm is good at identifying the peaks in the data and it provides
differing heights for peaks which match the data well. Some differences in
the peak heights between the data and the model are apparent but these can
mostly be attributed to the restriction that was in place of common peak lo-
cations across spectra.
When considering classifying new spectra it was found that the method
of classification could drastically change the percentage of correct classifica-
tions obtained. LDA and SVM provided consistently good results over both
datasets. The SVM method provided better results than LDA for the two
group classification in the melanoma dataset. This could be due to the sim-
plicity of the problem when compared with the 6 group case in the breast
cancer dataset or alternatively it could be due to the greater amount of train-
ing data available for this dataset. For the breast cancer dataset there were
only 4 spectra from each day of each group in the training set which may not
be a representative sample of the population of spectra. It is also possible
that the SVM method performed better than the LDA method because it is
more robust against distant observations on the wrong side of the boundary.
The possibility of some outliers being present is taken into account when con-
structing an SVM and the classification boundary should not alter much, if at
all, from the boundary if those outliers were excluded. However, in LDA the
presence of an outlier would skew the discrimination boundary.
When using LDA and SVM to classify, the results obtained using the algo-
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rithm were comparable with using the information contained in the compete
spectra despite the reduction in the number of available datapoints. This shows
promise for the use of data reduction methods to analyse high-dimensional pro-
teomic data.
Whichever method was used to classify new spectra in the breast cancer
dataset it was found that it was relatively easy to distinguish between the three
different types of spectrum (MCF-7/ADR, T47D or MCF-7). It was harder to
separate out control and treated specimens of the same type of cell line. Some
MCF-7/ADR spectra were misclassified into the MCF-7 group which should
not be surprising as they are both derived from the same original cell-lines.
In Mian et al. (2003) the breast cancer dataset was studied using artificial
neural networks (ANNs). This research highlighted the m/z values 10,518 Da,
11,100 Da, 11,687 Da and 13,239 Da as showing good classification ability be-
tween control and treated cell-lines. Only m/z values between 10 kDa and 15
kDa were considered in that analysis. The methods described in this chapter
provide similar results to two of these values at 11,133 Da and 11,701 Da.
These values are shown in tables 2.3 and 2.4 as some of the best classifiers of
the training data.
In Mian et al. (2005) the melanoma dataset was also studied using ANNs.
The research concluded that the best predictive capability came from the re-
gion between 2,000 Da and 5,000 Da and that very little predictive value was
obtained from the range between 10,000 Da and 15,000 Da. These observa-
tions are replicated in the work presented in this chapter. If we consider tables
2.9 and 2.10 we see that the majority of locations which best classify the data
are in the 2-5 kDa range and that no good classifiers exist between 10-15 kDa.
Indeed the only classifier with an m/z value greater than 10kDa is observed
at 28,160 Da. This location is one of the top three best classifiers identified in
this chapter.
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2.6 Summary
There are three main advantages to analysing spectra using the methods
considered in this chapter. Firstly, the initial peak finding method relies on
simple calculations which can be carried out quickly. The datasets considered
in this chapter were of length≈ 14,000. Fitting 150 peaks to one of the datasets
whilst also correcting the heights for peaks close to one another took around 90
seconds. This is a much quicker method of identifying peaks than the MCMC
analysis that will be carried out in chapter 3. Secondly, in the classification
step the new spectra are only being classified using the peak heights at each
location. This drastically reduces the dimension of the classification problem
from 144 × 14,000 to 144 × 150 for the breast cancer dataset and from 205
× 14,000 to 205 × 150 for the melanoma. Lastly when we compare with
traditional methods for data reduction, for example PCA, the peak finding
algorithm provides us with much more interpretable reasons for classification
into particular groups.
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Chapter 3
Modelling Mass Spectrometry
Data Using Markov Chain
Monte Carlo Simulation
3.1 Introduction
In section 1.5 an overview of some basic Bayesian theory and a short intro-
duction to the algorithms used in Markov Chain Monte Carlo (MCMC) was
presented. This chapter will consider the use of these methods to model the
available datasets. The initial model used in the MCMC simulations will be
introduced in section 3.2 and the results obtained from this are described in
section 3.3. More complex models are discussed in sections 3.4 and 3.5 and
the results are compared with those already obtained.
3.2 Modelling the Data
3.2.1 The Model
The aim is to use mass spectra to firstly differentiate between drug-treated
breast cancer cell-lines and non-treated controls as in Dryden et al. (2005),
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and Mian et al. (2003) who use neural networks; and secondly to differentiate
between stage I and stage IV melanoma as in Mian et al. (2005).
It can be noted from figures 3.1 and 3.2 that the spectra consist of a se-
quence of peaks of varying heights. Figure 3.1 shows sections of 6 spectra in
the breast cancer dataset, one from each of the groups, and figure 3.2 shows
sections of two spectra from the melanoma dataset, one from each of the two
stages. A possible modelling approach is therefore to fit a series of Gaussian
peaks to the data with locations, heights and variances to be estimated. This
approach can be implemented using the MCMC methods described in section
1.5 to construct samples from the joint posterior distribution of the unknown
parameters, namely the locations, heights and variances of the peaks.
The model used for each datapoint yis is distributed as yis ∼ N(θis, τ−1)
where the yis are independent of each other and where θis is the sum of scaled
Gaussian distributions:
θis =
k∑
j=1
hjs(ξµ
2
j)
− 1
2 exp
(
−1
2
(ξµ2j)
−1(xi − µj)2
)
(3.1)
where the index i = 1, . . . , p represents the position on the spectrum, xi is the
ith m/z value, s = 1, . . . , n is the spectrum number and j = 1, . . . , k is the
peak number. (The constant 1/(2π) has been subsumed in the hjs parame-
ters.) The parameters µj and hjs represent respectively the location and the
scaling that adjusts the height of the peaks in the model, and ξ is a constant of
proportionality that models the fact that the standard deviation of the peaks
increases linearly with the mean.
The means of the yis’s are similar due to the model formulation, however,
they are independent. The independence assumption on the yis’s holds because
the random errors are independent. There is no constraint that the integral of
the whole spectrum remains fixed.
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Figure 3.1: BREAST CANCER: Plots of the section of data between m/z
values 6,800 and 8,400 for replicate 1 in each of the six groups on day 4.
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Figure 3.2: MELANOMA: Plots of the section of data between m/z values
6,800 and 8,400 for replicate 1 in each of the two stages of melanoma.
The model we wish to fit has common locations µj (j = 1, . . . , k) and a
common constant of proportionality ξ across the spectra. The heights of each
peak are allowed to differ across spectra and the values of the hjs’s will indicate
the presence or absence of a peak at a particular m/z value. Using common
locations will enable us to determine the height difference between spectra at
any particular location.
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3.2.2 Priors for the Parameters
Variance parameters are restricted to be strictly positive values and so prior
distributions such as the normal should not be used. The conjugate prior for a
variance parameter with normal data is the inverse gamma distribution. This
is equivalent to a gamma prior on the precision parameter τ = 1/σ2. We are
considering vague priors for all the model parameters to try to ensure any
inferences come from the actual data and not because of strong prior infor-
mation. The vague gamma prior chosen for τ is Gamma(ǫ, ǫ) with ǫ = 0.001
which has mean ǫ
ǫ
= 1 and large variance ǫ
ǫ2
= 1
0.001
= 1000.
The parameter ξ describes the proportionality of peak standard deviation
to peak location. Since the peak standard deviation is constrained to be pos-
itive, the value of ξ must also be positive. A Uniform(0, 0.01) distribution
was used for the prior distribution in this case. The maximum possible peak
location is around 30 kDa which makes ξ × µ2 = 0.01× 900 = 9 and hence a
maximum peak standard deviation of 3 kDa.
The height scaling parameters h are similarly constrained to be positive.
However, plots of the data suggest that the heights are free to lie anywhere
within a restricted range of values. A suitably noninformative distribution of
this type is the uniform distribution and for this reason a Uniform(0, 100)
prior was chosen for these parameters.
When running the MCMC algorithms it is possible for the estimate of
one location parameter to become very close to another. If this continues it
is possible to have many parameters referring to the same peak and, in the
extreme case, all location parameters could become equal which would not
give biologically interpretable results. To ensure location parameters do not
become too close without good reason a Strauss prior is used (Kelly and Ripley,
1976). A Strauss prior has two parameters: an intensity β and a tolerance R
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and the joint distribution is:
π(µ1, . . . , µk) ∝ e−β(number of pairs of µ′js that are R-close). (3.2)
Here R-close means within tolerance R. The tolerance R is how close peaks
are allowed to be without penalty. The intensity β represents how strongly
one wishes to penalise a ‘close’ proposal - the higher the value of β the higher
the penalty. The use of this prior will penalise proposals where locations are
too similar such that if a proposed peak is too close to another, it will only
be accepted if it results in a higher posterior density. We use β = 4, 000 and
R = 100. This effectively ensures peaks cannot be within 100Da of each other
unless the posterior density is greatly increased by close peaks.
These priors and the likelihood given by the data model in equation (3.1)
are combined using Bayes’ Theorem to give the following posterior density
function
posterior ∝ π(y|ξ, µ, h, τ)π(ξ)π(τ)π(µ)π(h)
∝
p∏
i=1
n∏
s=1
τ
1
2 exp

−τ
2
[
yis −
k∑
j=1
hjs(ξµ
2
j)
− 1
2 exp
(
−1
2
(ξµ2j)
−1(xi − µj)2
)]2
× ǫ
ǫτ ǫ−1e−ǫτ
Γ(ǫ)
× e−β( number of pairs of µ′js that are R-close) (3.3)
where we assume that ξ, τ , µ and h are a priori independent. This is the
distribution from which we wish to sample parameter values.
3.2.3 Updating the Parameters
Throughout this section λ(t) will be used to denote the set of all the cur-
rent model parameters, and λ∗ will be used to denote the proposed set of
parameters. Since zero mean normal proposal distributions are used for all
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Metropolis-Hastings updates their ratio is equal to 1 and does not appear in
the acceptance probability calculations.
Updating τ
The complicated likelihood expression shown in equation (3.3) means the full
conditional distributions of most of the parameters cannot be written down
easily. However, the precision parameter τ is not involved in calculating θis
and thus its full conditional distribution can be easily determined. Hence, the
precision parameter τ is the only parameter in this model that can be updated
using conjugate Gibbs sampling. The full conditional distribution of τ is
P (τ |µ1, . . . , µk, h1,1, . . . , hks, ξ, y)
∝ τ pn2 +ǫ−1 exp
(
−τ
[
1
2
p∑
i=1
n∑
s=1
(yis − θis)2 + ǫ
])
i.e. τ ∼ Gamma
(
pn
2
+ ǫ ,
1
2
p∑
i=1
n∑
s=1
(yis − θis)2 + ǫ
)
.
(3.4)
So at each iteration of the MCMC algorithms a new value for τ will be drawn
from this distribution.
Updating ξ
When updating ξ the only part of the posterior that changes is the contribution
from the likelihood. The prior contribution remains the same since the prior
on ξ is uniform and thus is independent of the value of ξ. Assume that the
current value of ξ is ξt and the proposed value is ξ∗ ∼ N(ξt, σ2ξ ). Then the
equation for the acceptance probability α is:
α(λ(t), λ∗) = min
{
1,
π(y|λ∗)π(λ∗)
π(y|λ(t))π(λ(t))
}
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= min


1,
p∏
i=1
n∏
s=1
exp

−τ
2
[
yis −
k∑
j=1
hjs
(ξ∗µ2j)
1
2
exp
(
−(xi − µj)
2
2ξ∗µ2j
)]2
p∏
i=1
n∏
s=1
exp

−τ
2
[
yis −
k∑
j=1
hjs
(ξtµ
2
j)
1
2
exp
(
−(xi − µj)
2
2ξtµ2j
)]2


.
(3.5)
The move from ξt to ξ∗ is accepted with this probability and the ξ parameter
updated accordingly. Note that values of ξ outside the range (0, 0.01) have
zero prior and are consequently rejected.
Updating µ
When updating a peak location µ the posterior changes in two places - both
the likelihood and the prior contributions. Assume we are updating the j th
mean. Let µj,(t) be the j
th mean in the current set of parameters and µj,∗ ∼
N(µj,(t), σ
2
µj
) be the jth mean in the proposed set of parameters. Thus the
equation for the acceptance probability α in this case is:
α(λ(t), λ∗) =
min


1,
e−β(NR(µj,∗))
p∏
i=1
n∏
s=1
exp

−τ
2

yis − k∑
j=1
hjs
(ξµ2j,∗)
1
2
exp
(
−
(xi − µj,∗)
2
2ξµ2j,∗
)

2


e−β(NR(µj,(t)))
p∏
i=1
n∏
s=1
exp

−τ
2

yis − k∑
j=1
hjs
(ξµ2
j,(t))
1
2
exp
(
−
(xi − µj,(t))
2
2ξµ2
j,(t)
)

2




(3.6)
where NR(µj,·) is the number of peak locations within distance R of loca-
tion µj,·. This step updates just one of the peaks and should be repeated for
each location in the model.
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Updating h
When updating a height scaling h only the likelihood changes. Similar to the
updating procedure for ξ, the prior contribution remains the same since the
prior on h is uniform. Let h
(t)
js be the j
th scaling parameter of spectrum s in the
current set of parameters and h∗js ∼ N(h(t)js , σ2hjs) be the jth scaling parameter
on spectrum s in the proposed set of parameters. Thus the equation for α is:
α(λ(t), λ∗) = min


1,
p∏
i=1
exp

−τ
2
[
yis −
k∑
j=1
h∗js
(ξµ2j)
1
2
exp
(
−(xi − µj)
2
2ξµ2j
)]2
p∏
i=1
exp

−τ
2
[
yis −
k∑
j=1
h
(t)
js
(ξµ2j)
1
2
exp
(
−(xi − µj)
2
2ξµ2j
)]2


,
(3.7)
and the proposed value of the jsth scaling h is accepted with this probability.
As for the µ updates, this procedure only updates one peak height for one
spectrum and should repeated for each h in turn in every MCMC iteration.
3.2.4 The Adapting Stage
All the proposal distributions used in MCMC algorithms in this chapter are
N(µ, σ2) where µ is the current value of the parameter. The value of σ2 will
determine how many of the proposed parameter values are accepted. The value
of σ2 can be initialised but it is difficult to know before starting the MCMC if
this value is going to lead to the best acceptance rates.
To try to resolve this problem an adapting stage is built into the MCMC
procedure. The proportion of acceptances for each parameter updated using
Metropolis-Hastings should be around 40% to 60% to allow good mixing (Gel-
man, Roberts and Gilks, 1997). During the adapting stage the percentage of
acceptances for each parameter is monitored and each of the proposal vari-
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ances changed if the percentage is too low or too high. A general adapting
procedure for a particular parameter is (Browne and Draper, 2000):
1. Run through 100 iterations of the MCMC algorithms and calculate the
percentage of acceptances Pacc for that particular parameter in the last
100 iterations.
2. (a) if Pacc < 50% then decrease the variance of the proposal distribution
to σ2new = σ
2
old/(2− (Pacc50 )) and run for another 100 iterations.
(b) if Pacc > 50% then increase the variance of the proposal distribution
to σ2new = σ
2
old × (2− (100−Pacc50 )) and run for another 100 iterations.
3. When at least 300 iterations have been carried out (and every 100 itera-
tions thereafter) check to see if the 3 most recent values of Pacc lie within
the range 40% < Pacc < 60%.
4. (a) if the 3 most recent values of Pacc are not all within the range then
return to adapting the proposal variance as in step 2.
(b) if they are then the variance of the proposal distribution is accept-
able and is not changed further.
Then, once all the parameters have been initialised using this method, the
actual burn in process and main iterations can take place. An upper bound
is placed on the length of the adapting stage e.g. 5,000 iterations so that,
in the rare occasion that the variances of the proposal distributions are not
acceptable after such a time, the burn in period commences regardless.
3.2.5 Computational Speed Ups
The methods described in section 3.2.3 to update the parameter values are
theoretically correct. However, when they are used exactly as described they
are very computationally expensive. For example, when updating a height
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scaling parameter h, the calculation in equation (3.7) involves a complete re-
calculation of the posterior distribution with the proposed set of parameters.
However, since we only update one parameter at a time most of the posterior
distribution remains the same. The repeated calculation of all the other parts
therefore just wastes time which could better be used running the algorithm
for more iterations. Instead, to calculate the new posterior value we simply
subtract the contribution which has changed and add in the new contribution.
When a peak is placed at a particular location the value of θ is calculated
at every m/z value. When an m/z value is a large distance away from the peak
location the value of θ is almost zero. The calculation of lots of things that are
essentially zero also wastes time. To reduce the number of calculations needed
we restrict how far a peak is allowed to have an influence. This restriction is
set at a range of 6 of its standard deviations on either side of the mean. All
other m/z values are then set to zero for that peak.
We could also speed up the time taken to model the data by using the
High Performance Computing (GRID) system. Since each of the sections of
data is analysed separately we could run them in parallel. There are many
processors available and each section could be submitted to a different one.
This would reduce the total time taken to the longest time taken for any one
section. However, the parameters ξ and τ , which should be common across
sections, will now have to modelled separately in each.
3.2.6 The Splitting Algorithm
Full evaluation of the likelihood as shown in equation (3.3) is very time con-
suming. In order to model the data within a reasonable time we wish to split
the m/z values into distinct sections, where the dividing points are at low in-
tensity values. We can then update the heights of peaks in one section without
having to evaluate the whole likelihood.
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Assume we have n spectra each of length p. The idea is to split this dataset
into a partition of smaller sections of m/z values with lengths p1, p2, . . . , pm
such that
∑m
i=1 pi = p.
It is possible to split the dataset in a huge number of possible places. How-
ever, many of these ways will split one peak over two sections. We should try
to place split points so that the peaks in one section should not have much
effect on other sections.
The main aim of the analysis is to identify where spectra in different groups
have peaks of different heights. Biologically this could represent, for example,
a molecule that is more abundant in cancer patients than non-cancer patients
and which could be further analysed to introduce new drugs to treat the dis-
ease. However, there is only valuable information at and around peaks. There
is no valuable information to be gained at an m/z value where the relative
intensity is zero in all groups as this means that there are no molecules present
at all. Hence a sensible place to suggest splitting the data is where the rel-
ative frequency of molecules at that m/z value is close to zero. To ensure
that the split points have intensities as small as possible we consider the sum
over all spectra. These sums are shown in figure 3.3 for the breast cancer and
melanoma datasets respectively.
The splitting algorithm used is essentially binary - each section of the data
is split into two parts by the next step. To ensure that the algorithm does
not degenerate after the first split point is placed we need to be careful in how
future points are chosen. If, for example, the first datapoint available has the
lowest intensity then this would be chosen as the split point giving two parts,
one with length 1. This is not desirable and so we limit the range of m/z
values in which the split point can be found to the lower and upper quartiles
of the m/z values. The complete algorithm is detailed below.
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Figure 3.3: The sum of the data over all spectra in the breast cancer (left) and
melanoma (right) datasets respectively.
1. Sum the data over all spectra at each m/z value.
2. The splitting step:
• Calculate the lower quartile and upper quartile of the m/z values
in each section of data.
• Find the m/z value with the lowest intensity within each of these
interquartile ranges. Place split points at these locations.
3. For each new section of data that contains more than 1,200 m/z values
apply the splitting step again to this section.
The cut-off choice of 1,200 m/z values is arbitrary and was chosen as a
tradeoff between the speed of fitting the model and keeping the number of
sections relatively small. Using this algorithm the breast cancer data was split
into 17 sections and the melanoma data into 19 sections. The split points
chosen are shown in tables 3.1 and 3.2.
Each of the sections of data shown in tables 3.1 and 3.2 can now be anal-
ysed separately of the other sections in the dataset since we are assuming that
the fitted model will be close to zero at the ends of each partition. However,
this will involve the use of different τ and ξ parameters in each section.
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m/z 3022 4187 5167 6056 7587 8266 9937 10728 13053
length 1115 1057 779 645 1008 414 952 423 1159
m/z 14948 16735 19128 19957 21110 24357 27149 29994
length 771 870 971 322 437 1170 945 914
Table 3.1: Split points obtained from the algorithm for the breast cancer data
and the number of m/z values in each part.
m/z 2652 3621 4388 5668 7415 8497 9916 10692
length 737 942 659 982 1175 659 804 415
m/z 11367 13465 15652 16417 18604 19409 20695 23734
length 349 1023 985 328 898 317 493 1108
m/z 24790 26735 29994
length 368 658 1051
Table 3.2: Split points obtained from the algorithm for the melanoma data
and the number of m/z values in each part.
3.3 Application to Datasets
The methods outlined in the previous two sections are now applied to both
the breast cancer dataset and the melanoma dataset. Each dataset ranges over
the same m/z values - 2,000 Da to 30,000 Da. The sections of data obtained
by using the splitting algorithm detailed in the previous section were modelled
separately and the results combined.
To find suitable starting values for the parameters we use the peak find-
ing method detailed in chapter 2. This has two main benefits. Firstly if the
parameters start in reasonable places the amount of time the algorithm takes
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to adapt the proposal variances may be reduced. Secondly, and more impor-
tantly, given starting values based on peak size, it is unlikely that a prominent
peak will be ignored. With random starting values this may not be the case
as parameters could converge elsewhere.
The number of peaks to be fitted to the data differed between each sec-
tion. The number of visible peaks was counted and then this number was
increased to account for any hidden peaks. This should not affect the results
of the MCMC as the fitted heights of the extra peaks can be close to zero if
no peak is present. For each section the adapting stage was used to fine-tune
the parameter values before a burn in of 1,000 iterations and an MCMC run
of 5,000 iterations. The adapting stage took 3,000 iterations on average before
the proposal acceptance rates were suitable.
3.3.1 Results for the Breast Cancer Dataset
As explained in section 3.2, the model parameters included peak locations
(µj), peak heights (hjs), a proportionality constant (ξ) used to model the peak
variances, and a residual variance parameter (1/τ). The current parameter
values were checked at each iteration to determine the maximum a posteriori
(MAP) parameter estimates.
In figure 3.4 one complete spectrum from the dataset is shown (black) along
with the fitted model using the MAP parameter estimates (red). In total 138
peaks have been modelled. A smaller section of the dataset, between 7,600 Da
and 8,300 Da, is shown in figure 3.5. This figure shows all the adcon spectra
grouped by day. Similarly to figure 3.4, the black lines show the data and the
red lines the MAP estimates, and table 3.3 shows the parameter values that
are used to construct these MAP estimates.
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Figure 3.4: A single breast cancer spectrum and its fitted model. The black
line shows a single spectrum from the breast cancer dataset and the red line
shows the fitted model using the MAP parameter estimates.
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Figure 3.5: A section of the MAP after 5,000 iterations and original data for
all 24 spectra in the adcon group on each day separately. The black lines show
sections of the spectra from the breast cancer dataset and the red lines show
the fitted models using the MAP parameter estimates.
parameter ξ τ µ1 µ2 µ3 µ4 µ5
MAP value 0.000039 3.5862 8110 7904 7694 7939 8212
Table 3.3: The MAP estimates of ξ, τ and the five location parameters µj for
the section of the breast cancer data shown in figure 3.5.
96
3.3 Application to Datasets
The MAP estimates of θ shown in figures 3.4 and 3.5 seem to approximate
the spectra quite well and the visible peaks have been identified by the model.
However, some of the fitted heights are not very accurate for some peaks, for
example the peak at around m/z value 8,100 Da on all four days. Here the
modelled heights are not as large as the data. This could be attributed to the
non-normal shape of this peak which is most evident on day 4.
Convergence of the parameters can be checked by inspecting trace plots.
Figure 3.6 shows the trace plots for the precision parameter τ and the propor-
tionality parameter ξ and figure 3.7 shows the trace plots for the five location
parameters µj which relate to the section of data shown in figure 3.5.
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Figure 3.6: Trace plots of the precision parameter τ (left) and the proportion-
ality constant ξ (right) for a section of the breast cancer dataset.
Trace plots for the 720 height scaling parameters are omitted. There ap-
pear to be no patterns in most of the traces which implies the chains are
mixing well and that the adapting and burn-in period are of a suitable length.
In the case of peak 5, shown in figure 3.7, the trace appears skewed in one
direction. This is because this location was close to the end of this section of
data and proposals out of the range were immediately rejected. The trace for
peak 4 centres around an m/z value of 7,940 Da and appears to have a smaller
acceptance probability than the others. This peak location is close to a more
important peak in the model centred around 7,905 Da.
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Figure 3.7: Trace plots of the five location parameters µj for a section of the
breast cancer dataset.
To see how well the model fits the data the Akaike Information Criterion
(AIC) statistic can be calculated (Akaike, 1974). The number of parameters
in the model is comprised of 138 locations, 19,872 heights, 17 residual vari-
ances and 17 proportionality constants (each of the 17 sections had a separate
estimate of ξ and τ). For the model used in this section the AIC is thus
−2 × loglikelihood + 2× no. of parameters
= (−2× 1, 317, 360) + (2× 20, 044)
= −2, 594, 632. (3.8)
This value will be used in the rest of this chapter to determine whether more
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complex models are appropriate. Similarly, the BIC statistic for this model is
−2, 343, 817. Comparisons of the models using the AIC and BIC statistics will
be discussed later.
For each day and at each peak location in the model t-statistics (Student,
1908) were calculated using the maximum posterior estimates of the height
parameters to identify which locations differed in height between the related
pairs of control and treated cell-lines (e.g. adcon and adtax ). Pairwise com-
parisons between the three control cell-lines (e.g. tdcon and mccon) were also
calculated. Due to the large number of tests a false discovery rate algorithm
was used (see section 1.6.6) to reduce the number of results identified as sig-
nificant. The results of these analyses are shown in tables 3.4 and 3.5. The
numbers in the tables indicate which day(s) had significant t-statistics after the
FDR algorithm had been applied with q∗ = 0.05. Similar statistics were also
calculated which ignored the day information. However, under this assumption
none of the locations differed significantly in height for any of the comparisons.
It appears from tables 3.4 and 3.5 that it is easier to distinguish between
groups on days 3 and 4. This should be expected since the Taxol treatment
will have had more time to take effect. In most cases of the control-treated
comparisons the t-statistics were positive suggesting that the Taxol treated
cell-lines have smaller heights. Also it should be noted that significant differ-
ences between adcon and adtax cell-lines do not occur very often - the only
exception occurring at an m/z value of 5,407 Da. This should also not be
surprising since the MCF-7/ADR cell-lines are meant to be resistant to Taxol.
We should be careful when using these m/z values to show differences
between groups as inference is based on only 6 observations per group. Tests
using such small amounts of data lack power and much more data would be
needed to obtain reliable biomarkers.
99
3.3 Application to Datasets
m/z 2959 3053 3709 3809 3835 4019
adc/tdc (3) (4)
adc/mcc (3) (2)
tdc/mcc (1) (4) (4) (3,4) (3,4)
m/z 4119 4388 4541 4641 4703 4803
adc/tdc (4) (4)
adc/mcc (4) (3,4) (2,3) (2,3,4)
tdc/mcc (3,4) (4) (3,4) (2,4) (4)
m/z 4887 5103 5253 5376 5669 6916
adc/tdc (4) (3) (4)
adc/mcc
tdc/mcc (1,2,3,4) (2,4) (3,4) (2) (3,4)
m/z 7147 7443 7694 7939 8110 8212
adc/tdc (3) (4) (4) (4)
adc/mcc (4) (2,4) (4)
tdc/mcc (2,4) (2,3) (3,4)
m/z 9187 10016 10230 10435 11137 11357
adc/tdc (3)
adc/mcc (3) (4)
tdc/mcc (3,4) (2) (2,3) (3) (3)
m/z 13636 14046 14250 15402 17252 17764
adc/tdc (4) (4) (4)
adc/mcc
tdc/mcc (3) (3) (3) (3,4) (3) (2,4)
m/z 19030 20360 21010 23083
adc/tdc (2) (4) (4)
adc/mcc
tdc/mcc (1) (4)
Table 3.4: The peak locations with significant t-statistics between the three
pairs of control groups.
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m/z 3592 4389 4703 5407 5669 6369
adc/adt (3)
tdc/tdt (2) (4) (4) (2)
mcc/mct (4) (4)
m/z 7019 8110 8473 10228 11719 12389
adc/adt
tdc/tdt (4) (3) (3)
mcc/mct (4) (4) (4)
m/z 12643 13432 13636 14046 14460 14856
adc/adt
tdc/tdt (3) (3)
mcc/mct (4) (4) (4) (4) (4)
m/z 15043 15402 16315 17983 18506 19030
adc/adt
tdc/tdt (3) (1)
mcc/mct (4) (4) (4) (4) (4)
m/z 20815 21010 22227 23083 24117 25373
adc/adt
tdc/tdt (3) (1) (3)
mcc/mct (4) (4) (4) (4)
Table 3.5: The peak locations with significant t-statistics between the pairs of
control and treated cell-lines.
3.3.2 Results for the Melanoma Dataset
One complete melanoma spectrum (black) is shown in figure 3.8 along with
the fitted model using the MAP parameter estimates (red). In total 112 peaks
have been modelled. To see the model more clearly, a smaller section of the
dataset, between 7,400 Da and 8,500 Da, is shown in figure 3.9.
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Figure 3.8: A single melanoma spectrum and its fitted model. The black line
shows a single spectrum from the melanoma dataset and the red line shows
the fitted model using the MAP parameter estimates.
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Figure 3.9: A section of the MAP after 5,000 iterations and original data for
6 spectra in each of the melanoma stages separately.
parameter ξ τ
MAP value 0.000020 0.4306
parameter µ1 µ2 µ3 µ4 µ5 µ6 µ7 µ8
MAP value 7788 7988 8158 7888 7672 8368 8258 7572
Table 3.6: The MAP estimates of ξ, τ and the eight location parameters µj
for the section of the melanoma data shown in figure 3.9.
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Figure 3.9 shows 6 spectra from each of the stages of melanoma. Again,
the black lines show the data and the red lines the MAP estimates. The MAP
estimates for each of the model parameters are given in table 3.6.
The MAP estimates of θis model the data well albeit with a similar problem
to the breast cancer data in that some of the fitted heights are not sufficiently
large to correctly match the data. This can be seen in figure 3.9 where the
MAP at an m/z value around 7,800 Da falls short of the datapoints.
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Figure 3.10: Trace plots of the eight location parameters µj for the melanoma
dataset.
We again check convergence of the parameters by inspecting trace plots.
Figure 3.10 shows the trace plots for the eight location parameters µj and figure
3.11 shows the trace plots for the precision parameter τ and the proportionality
parameter ξ. Trace plots for the 1,640 height scaling parameters are omitted.
In general the traces are acceptable as there are no obvious patterns.
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Figure 3.11: Trace plots of the precision parameter τ (left) and the propor-
tionality constant ξ (right) for a section of the melanoma dataset.
In table 3.7 are the m/z values with significant t-statistics between the two
stages of melanoma after the FDR algorithm has been applied with q∗ = 0.05.
The majority of the statistics are positive which suggests that as the stage of
melanoma increases the abundance of molecules at these m/z values decreases.
All of the significant peaks in the range 11,300 - 12,200 Da have negative t-
statistics which suggests an increase in the number of molecules between stage
I and stage IV. The melanoma results are more reliable than the breast cancer
results as they are based on a larger amount of information.
The AIC statistic can be calculated as for the breast cancer dataset. The
number of parameters in the model is comprised of 112 locations, 22,960
heights, 19 residual variances and 19 proportionality constants (each of the
19 sections had a separate estimate of ξ and τ) and thus for the single peaks
model the AIC is (−2× 2, 811, 217) + (2× 23, 110) = −5, 576, 214. Similarly,
the BIC statistic for this model is −5, 278, 873. Comparisons of the models
using the AIC and BIC statistics will be discussed later.
In the fitted models for both the breast cancer and the melanoma there are
some height parameters which are not as large as the data. To try to improve
the fit more complex models are now introduced.
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m/z 2227 2262 2306 2488 2539 2766
t-statistic 8.077 6.316 5.400 7.885 5.741 5.687
m/z 2962 3298 3556 3828 3888 3974
t-statistic 7.310 5.231 4.681 8.500 9.085 4.294
m/z 4478 4656 4778 5107 6455 6652
t-statistic 4.198 4.836 4.898 4.738 5.860 5.342
m/z 6752 7572 7672 7788 7988 8158
t-statistic -5.408 7.988 7.443 7.410 5.769 5.500
m/z 8368 8928 9323 9481 9670 11528
t-statistic 5.043 4.845 4.860 5.458 4.555 -5.499
m/z 11704 13946 14210 14659 17234 17424
t-statistic -5.471 5.155 6.951 6.350 4.619 5.151
m/z 17810 18207 28172 28745 29233
t-statistic 5.270 4.525 7.566 6.905 6.479
Table 3.7: The peak locations with significant t-statistics between the two
stages of melanoma.
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3.4 Double Peaks
As pointed out in section 3.3.1, the peak present in the breast cancer dataset
at an m/z value of 8,100 Da in figure 3.5 does not look Gaussian and thus the
model does not fit well to the data at this location. On further examination
of this peak it appears to possibly consist of a combination of two peaks at
the same location. The first is a peak with small variance which accounts for
the spikiness of the overall peak, and the second is a peak with larger variance
which contributes a baseline amount of intensity.
In the model discussed in section 3.2.1 peaks were fitted at certain m/z
values and the standard deviation of these peaks was proportional to the lo-
cation. To take the combination peaks into account a slight alteration of the
model is needed. At each peak location two peaks will now be fitted. The first
will be fitted as in the previous model and the second will be fitted to exactly
the same location but will have an increased variance.
3.4.1 The Double Peaks Model
Each datapoint yis is distributed as yis ∼ N(θis, τ−1) where θis is changed to:
θis =
k∑
j=1
hjs(ξµ
2
j)
− 1
2 exp
(
−1
2
(ξµ2j)
−1(xi − µj)2
)
+
k∑
j=1
h∗js(ωξµ
2
j)
− 1
2 exp
(
−1
2
(ωξµ2j)
−1(xi − µj)2
)
(3.9)
where the index i = 1, . . . , p represents the position on the spectrum, xi is the
ith m/z value, s = 1, . . . , n is the spectrum number, j = 1, . . . , k is the peak
number, ξ is the constant of proportionality and µj are the peak locations.
Note that the two peaks have the same location but the second peak has a
larger variance by a factor of ω > 1. From preliminary analysis it appeared
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that ω = 2 was a reasonable choice. We fix this parameter initially and exam-
ine different variances in section 3.5.
The parameters hjs represent the scaling that adjusts the height of the
peaks with small variance and the parameters h∗js are similar for the peaks
with large variance.
As in the previous section, the model will be fitted to each section of data
separately and the results pooled to obtain an overall model. The results are
presented in the next section.
3.4.2 Results for the Breast Cancer Dataset
To compare with the single peaks model 138 peaks have again been modelled.
A small section of the dataset, between 7,600 Da and 8,300 Da, is shown in
figure 3.12. This figure shows one spectrum in the adcon group from day 4.
The black line shows the data, the red line shows the MAP estimate of θ under
the single peaks model and the green line shows the MAP estimate under the
double peaks model. Table 3.8 shows the parameter values that give the MAP
estimate under the double peaks model.
Comparing the two models we see that the double peaks model provides a
better fit to the data than the single peaks model for the peak at 8,100 Da as
the fitted heights are increased, better matching the data. However, the fit is
still not perfect as the fitted heights remain smaller than the data. When the
MAP parameter estimates in table 3.8 are compared with those for the single
peaks model it can be seen that the peak locations have not changed greatly.
The proportionality parameter has decreased from its value in the single peaks
model. Since ξ no longer has to solely account for the variance of the complete
peaks a smaller value allows the peaks with smaller variance to be modelled
more closely.
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Figure 3.12: A section of the MAP after 5,000 iterations using single peaks
(red), double peaks (green) and original data for one spectrum in the adcon
group from day 4.
parameter ξ τ µ1 µ2 µ3 µ4 µ5
MAP value 0.000024 5.5413 8111 7911 7694 7936 8211
Table 3.8: The MAP parameter estimates for the section of the breast cancer
data shown in figure 3.12 using the double peaks model (green).
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Trace plots for all the modelled parameters were checked. There were
no evident patterns except for the one sided proposals for one peak due to
its proximity to the end of the section. To compare this model with the
one in the previous section we recalculate the AIC. The number of param-
eters in the model is comprised of 138 locations, 39,744 heights, 17 residual
variances and 17 constants. For the double peaks model the AIC is thus
(−2 × 1, 585, 413) + (2 × 39, 916) = −3, 090, 994. This value is lower than
that of the single peaks model and so the double peaks model is an improve-
ment when using this criterion. The BIC statistic for this model is −2, 591, 523.
As with the single peaks model t-statistics were calculated between pairs
of control groups (on each day separately and combined) and also between
similar control/treated pairs (on each day separately and combined). The
tests were carried out on the MAP estimates of θ at each peak location and
the false discovery rate algorithm was again used because of multiple testing.
The peaks exhibiting significant differences between the groups remain almost
identical to the ones identified in tables 3.4 and 3.5. Again combining days
resulted in no significant results.
3.4.3 Results for the Melanoma Dataset
Figure 3.13 shows one spectra from the melanoma dataset over the same range
of m/z values as examined previously. The black line shows the data and the
red and green lines the MAP estimates of θ under the single and double peaks
models respectively. The MAP parameter estimates under the double peaks
model which were used to construct the green curve are shown in table 3.9.
From figure 3.13 we can see that the double peaks model again provides a
better fit to the data than the single peaks model for the peak at 7,800 Da as
the fitted heights are increased. The MAP estimate of θ for the area between
m/z values of 7,900 Da and 8,000 Da is more accurate.
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Figure 3.13: A section of the MAP after 5,000 iterations using single peaks
(red), double peaks (green) and original data for one spectrum in the melanoma
dataset.
parameter ξ τ
MAP value 0.000015 0.8547
parameter µ1 µ2 µ3 µ4 µ5 µ6 µ7 µ8
MAP value 7787 7887 8160 7991 7681 8370 8260 7581
Table 3.9: The MAP parameter estimates for the section of the melanoma
data shown in figure 3.13 using the double peaks model (green).
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No patterns were visible in the trace plots for the parameters so the chains
were mixing in an acceptable manner.
To find peaks with significantly different heights between the two stages of
melanoma t-statistics were calculated using the MAP estimates of θ at each
peak location and the FDR algorithm. The significant locations remain essen-
tially the same as in the single peaks model and the signs of the majority of
significant t-statistics remain positive showing that the heights of the peaks in
stage IV are lower than in stage I.
To compare with the previous model for this dataset we calculate the
AIC. The model contains 112 location parameters, 45,920 heights, 19 resid-
ual variances and 19 constants. For the double peaks model the AIC is thus
(−2 × 2, 908, 745) + (2 × 46, 070) = −5, 725, 350. Similarly to the results for
the breast cancer data this AIC value is much lower than for the single peaks
model and we conclude that, out of these two options, the double peaks model
is much more preferable using this criterion. The BIC statistic for the double
peaks model is −5, 132, 598. The statistic has increased compared with that
in the single peaks model as a penalty has been imposed for the introduction
of nearly twice the number of parameters.
A more complex model will now be developed which incorporates the non-
symmetry of some of the peaks.
3.5 Peak Offsetting
When analysing a substance by mass spectrometry it is common practice to
carry out two sets of analyses - with different resolutions. The resolution will
determine how well the mass spectrometer can differentiate between molecules
at m/z values close to each other. The first analysis is carried out with a
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standard resolution and the results studied to find sections of the spectrum
that warrant further attention. The second analysis is then carried out with
a much higher resolution on only these sections of data. More precise data is
obtained and more accurate differences can be identified. See figure 3.14 for
an example of a chemical compound’s mass spectrum showing a single peak
studied at higher resolution.
Figure 3.14: The mass spectrometry results for a single peak using a machine
with higher resolution. From Wiley, J. & Sons (2006)
The data we are considering was obtained using a mass spectrometer with
a standard resolution of 0.2%. This results in spectra resembling the ‘series of
Gaussian peaks’ that has been mentioned already. As shown in figure 3.14 a
peak may consist of many spikes. Spikes within the same peak can represent
either a completely different molecule or the same overall molecule with slight
modifications.
An m/z value is essentially a measure of mass. The mass of a molecule can
be changed in two ways. Firstly an atom can have larger mass than normal if
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it is an isotopic variant. For example, there are 3 different isotopes of hydrogen
- hydrogen, deuterium and tritium - which have relative masses of 1, 2 and 3
respectively. If a molecule contains some of these isotopic variants it will have
greater mass and thus its spike will appear at a different m/z value to the
original molecule. Secondly post-translational modifications can occur. Before
mass spectrometry of the sample takes place it is possible that the structure of
some proteins could change, for example via the attachment of another func-
tional group. When the results are obtained the spike for the new bigger ion
will appear at an m/z value greater than the original.
From this it can be seen that fitting a double peaks model is a move in
the right direction since many spikes make up the overall peak. However, the
restriction of equating locations is not necessarily sound. The peaks in the data
are much more likely to have longer right hand tails due to isotopic variation
and post-translational modifications. To account for this the locations of the
peaks with larger variance could be altered from µj to µj + δj . The double
peaks model is adjusted accordingly in the next section.
3.5.1 The Offset Peaks Model
To model the offset peaks we slightly alter the equation for θis described in
section 3.2.1. Each peak location still combines two peaks - the first will be
fitted as in both the previous models and the second will be fitted to a location
within δj to the right of the location µj.
Each datapoint yis is distributed as yis ∼ N(θis, τ−1) where θis is now:
θis =
k∑
j=1
hjs(ξµ
2
j)
− 1
2 exp
(
−1
2
(ξµ2j)
−1(xi − µj)2
)
+
k∑
j=1
h∗js(ωξ(µj + δj)
2)−
1
2 exp
(
−1
2
(ωξ(µj + δj)
2)−1(xi − (µj + δj))2
)
(3.10)
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where the index i = 1, . . . , p represents the position on the spectrum, xi is the
ith m/z value, s = 1, . . . , n is the spectrum number, j = 1, . . . , k is the peak
number, ξ is the constant of proportionality and µj are the peak locations. The
δj parameters model the offset from the main location µj of the second peaks.
It is possible for a δj to be zero if no offset is present. The variance scaling
factor for the double peaks is modelled by ω. The parameters hjs represent
the scaling that adjusts the height of the peaks with small variance and the
parameters h∗js are similar for the offset peaks with larger variance.
The MCMC algorithm is altered to incorporate another Metropolis-
Hastings step for the offset parameters δj. A uniform δj ∼ Unif(0, 0.1) prior
was used for these parameters. Since we are only considering offsets to the
right the minimum offset possible is 0. The maximum offset is set to be 0.1
since it is possible for another peak to be present if the m/z value is greater
than 100 Da away. When updating a δj the only part of the posterior that ac-
tually changes is the contribution from the likelihood. The prior contribution
remains the same since the prior on δj is uniform. Assume that the current
value of δj is δj,t and the proposed value is δj,t+1 ∼ N(δj,t, σ2δ ). Then the
equation for α, the acceptance probability, is:
α(λ(t), λ∗) = min


1,
p∏
i=1
n∏
s=1
exp
(
−τ
2
[yis − θ∗is]2
)
p∏
i=1
n∏
s=1
exp
(
−τ
2
[
yis − θ(t)is
]2)


.
(3.11)
where θ∗is is the proposed value of θis (see equation (3.10)) under the proposed
set of parameter values. The move from δt to δ∗ is accepted with this proba-
bility and the δj parameter updated accordingly. Note that values of δ outside
the range (0, 0.1) are assumed to have zero prior and are not considered. This
step is repeated for each of the peaks.
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3.5.2 Offset Peaks and Differing Variances
In the following results section we consider two possibilities. Firstly we main-
tain the restriction that the ω parameters are all equal to 2 and secondly, to
make the model as general as possible, we allow these variance scaling param-
eters to vary at each peak. For this new model the ω parameters will have a
prior distribution ω ∼ Unif(1.5, 10). We do not wish the variances of the two
peaks at the same location to become equal so the lower bound was set to be
1.5. The upper bound was set to 10 to allow locations to mainly consist of a
single peak.
The MCMC algorithm is altered to incorporate another Metropolis-
Hastings step for the variance scaling parameters ωj. When updating an ωj the
posterior only changes through the likelihood. The prior contribution remains
the same since the prior on ωj is uniform. Assume that the current value of
ωj is ωj,t and the proposed value is ωj,t+1 ∼ N(ωj,t, σ2ω). Then the acceptance
probability α is calculated as in equation (3.11) and the move from ωj,t to
ωj,t+1 is accepted with this probability. Note that values of ωj outside the
range (1.5,10) have zero prior and are not considered. This step is repeated
for each of the peaks.
In summary, the four models considered in this chapter are:
model section
I single Gaussian peaks 3.2
II double peaks mixture model 3.4.1
III offset peaks mixture model 3.5.1
IV offset peaks with differing variances 3.5.2
Table 3.10: A summary of the four models considered in this chapter.
The results from these models will now be presented.
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3.5.3 Results for the Breast Cancer Dataset
To enable suitable comparisons to be drawn with the previous models, 138
peaks have again been modelled. Figure 3.15 shows the same section of data
as before but with the MAP estimates of θ under all four models considered in
this chapter. The black lines show the data, the red lines the MAP estimates
of θ under the single peaks model, the green line the MAP under the double
peaks model, the turquoise line the MAP under the offset peaks model and the
blue line the MAP under the differing variances model. Table 3.11 shows the
parameter values that give the MAP estimate under the offset peaks model
(turquoise) and table 3.12 the parameter values under the differing variance
model (blue).
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Figure 3.15: A section of the MAP after 5,000 iterations using all the models
and original data for one spectrum in the adcon group for day 4. The red line
shows the MAP under the single peaks model, the green line the double peaks
model, the turquoise line the offset peaks model and the blue line the differing
variances model.
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parameter ξ τ
MAP value 0.000022 8.671
parameter µ1 µ2 µ3 µ4 µ5
MAP value 8106 7834 7664 7931 8265
parameter µ1 + δ1 µ2 + δ2 µ3 + δ3 µ4 + δ4 µ5 + δ5
MAP value 8141 7920 7711 7962 8266
Table 3.11: The MAP parameter estimates for the section of the breast cancer
data shown in figure 3.15 under the offset peaks model (turquoise).
parameter ξ τ
MAP value 0.000017 9.703
parameter µ1 µ2 µ3 µ4 µ5
MAP value 8110 7843 7671 7951 8264
parameter µ1 + δ1 µ2 + δ2 µ3 + δ3 µ4 + δ4 µ5 + δ5
MAP value 8137 7922 7720 8151 8265
parameter ω1 ω2 ω3 ω4 ω5
MAP value 1.50 1.74 2.03 3.42 1.68
Table 3.12: The MAP parameter estimates for the section of the breast cancer
data shown in figure 3.15 under the differing variances model (blue).
From figure 3.15 we can see that the offset peaks model again provides
a better fit to the data than the previous models for the peak at 8,100 Da.
The fitted heights are increased further, better matching the data although
there still remains some difference. For the purposes of model comparison we
recalculate the AIC. The number of parameters in the model is comprised of
138 locations, 39,744 heights, 138 offset parameters, 17 residual variances and
17 proportionality constants. For the model used in this section the AIC is
thus (−2× 2, 182, 023)+ (2× 40, 056) = −4, 283, 938. This value is lower than
that of the double peaks model and so the offset peaks model is a further im-
provement. The BIC statistic for the offset peaks model is −3, 782, 705. The
statistic has again lowered from that in the double peaks model and so the
offset peaks model is an improvement.
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The difference between the data and the fitted model is slightly reduced by
the use of the more complicated model with differing variances, however, this
new model does not appear to give a much better fit to the data shown than
that under the offset model. The more complicated model must fit better in
other places, however, as we see a reduction in the AIC and BIC. The number
of parameters in the model is comprised of 138 locations, 39,744 heights, 138
offset parameters, 138 variance scaling parameters, 17 residual variances and
17 proportionality constants. For the model used in this section the AIC is
thus (−2×2, 188, 279)+(2×40, 192) = −4, 296, 174 and the BIC is −3, 793, 243.
Trace plots for all the modelled parameters were checked in both models.
There were no evident patterns except for the proposals only accepted in one
direction for one peak due to its proximity to the end of the section.
When the MAP parameter estimates in tables 3.11 and 3.12 are compared
with those for the previous models we see that the peak locations have again
not changed much. The offset parameters for visible peaks are all positive and
the variance scaling parameters are all around the value 2. For the fifth peak
it is seen that the value of δ5 is zero as the offset peak is fitted to effectively
the same location. The value of the proportionality parameter has decreased
although not by as much as last time.
The t-statistics using the MAP estimates of θ between pairs of control
groups and between related control/treated groups did not show any signifi-
cantly different peak locations compared with those of the original single peaks
model for either of the offset models, although the absolute value of a large
number of the t-statistics has increased. Comparisons which ignored day in-
formation all remained insignificant. The significant peak locations after cor-
recting for multiple testing can be seen in tables 3.4 and 3.5.
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3.5.4 Results for the Melanoma Dataset
The same small section of the dataset as examined previously is shown in figure
3.16 along with the MAP estimates of θ for each of the four models. Figure
3.16 shows one spectrum from the melanoma dataset - the black line shows the
data and the red, green, turquoise and blue lines the MAP estimates of θ under
the single peaks, double peaks, offset peaks and differing variance peaks mod-
els respectively. Tables 3.13 and 3.14 show the parameter values that are used
to construct the MAP estimates of θ under the offset peaks model (turquoise)
and differing variances model (blue).
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Figure 3.16: A section of the MAP after 5,000 iterations using offset peaks and
original data for one spectra in the melanoma dataset. The red line shows the
MAP under the single peaks model, the green line the double peaks model, the
turquoise line the offset peaks model and the blue line the differing variances
model.
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parameter ξ τ
MAP value 0.000012 1.526
parameter µ1 µ2 µ3 µ4 µ5 µ6 µ7 µ8
MAP value 7789 8163 8267 7989 7665 8369 7889 7453
parameter µ1+δ1 µ2+δ2 µ3+δ3 µ4+δ4 µ5+δ5 µ6+δ6 µ7+δ7 µ8+δ8
MAP value 7869 8196 8267 8035 7748 8372 7954 7544
Table 3.13: The MAP parameter estimates for the section of the melanoma
data shown in figure 3.16 under the offset peaks model (turquoise).
parameter ξ τ
MAP value 0.000005 2.422
parameter µ1 µ2 µ3 µ4 µ5 µ6 µ7 µ8
MAP value 7775 7875 8149 7996 7669 8363 8249 7473
parameter µ1+δ1 µ2+δ2 µ3+δ3 µ4+δ4 µ5+δ5 µ6+δ6 µ7+δ7 µ8+δ8
MAP value 7814 7940 8175 8048 7723 8392 8290 7502
parameter ω1 ω2 ω3 ω4 ω5 ω6 ω7 ω8
MAP value 2.04 2.69 3.40 3.06 1.60 1.89 2.71 2.39
Table 3.14: The MAP parameter estimates for the section of the melanoma
data shown in figure 3.16 under the differing variances model (blue).
From figure 3.16 we can see that the offset peaks model does not appear
to show much difference in the range shown compared with the double peaks
model. However, when considering the AIC we see a reduction so the model
provides a better fit in some areas of the data using this criterion. The number
of parameters is 46,182 (112 locations, 45,920 heights, 112 offset parameters,
19 residual variances and 19 proportionality constants). For the model used in
this section the AIC is thus (−2 × 3, 136, 830) + (2× 46, 182) = −6, 181, 296.
This lower value indicates that the offset peaks model is an improvement upon
the double peaks model. The BIC statistic is −5, 587, 103 which is lower than
that of both the single and double peaks models.
When comparing the MAP estimates of θ from the differing variances
model with those from the simpler offset peaks model it can be seen that
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the more complicated model gives a much better fit to the data shown. The
height of the peak at around 7,800 Da is much more closely fitted and the
range between 7,900 and 8,000 Da is an improvement over all the previ-
ous models. This is borne out by a reduction in the AIC. The number of
parameters in the differing variances model is 46,294 (112 locations, 45,920
heights, 112 offset parameters, 112 variance scaling parameters, 19 residual
variances and 19 proportionality constants). For this model the AIC is there-
fore (−2×3, 146, 468)+(2×46, 294) = −6, 200, 348 and the BIC is −5, 604, 714.
All the offset parameters applying to visible peaks are non-zero so none of
the peaks in the range are symmetrical. This was also true for the majority of
the peaks in the other parts of the dataset. This suggests that the assumption
of peaks having longer right hand tails was sensible. The value of the offset
peak µ8 + δ8 given in table 3.13 has moved 100 Da to the right compared with
µ8. This is the upper limit of the permissible values for a δ. We can see from
figure 3.16 that the relative intensity at both the m/z values is negligible and
so this causes no problem. In the final model the variance scaling parameters
ω seem to be around the value 2 which suggests our previous model using a
standard scaling of 2 was not unreasonable.
No patterns were visible in any of the trace plots for the parameters so
the chains were acceptable. To check if any peaks were different between
the two stages of melanoma t-statistics were again calculated using the MAP
estimates of θ at each peak location and then correcting for multiple testing.
The locations remain essentially the same as in the previous two models and
the majority of the t-statistics are positive showing that the heights of the
peaks in stage IV are lower than in stage I. However, at around 11,500 to
11,900 Da the t-statistics show the opposite. In Mian et al. (2005) the area
around 11,701 Da was identified as one showing significant variability in the
data. The absolute value of the majority of t-statistics increases under the two
offset peaks models.
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3.6 Summary
In this chapter we have shown how MCMC algorithms can successfully be
used to simulate from a model for mass spectrometry data and also how we
can incorporate the peak finding procedure from chapter 2 to provide a suit-
able starting point. The use of these methods greatly reduces the dimension
of the datasets to a relatively small number of parameters. The number of
datapoints are 2,009,088 and 2,859,955 for the breast cancer and melanoma
datasets respectively. For the final model in this chapter the respective num-
bers of modelled parameters were 40,192 and 46,294 - around 2% of the original
number of datapoints in each case.
It has been shown that it is important to consider the data not as a com-
bination of single peaks but as a combination of double peaks with offset
locations. Using the AIC calculations it is seen that using offsets to model
the peaks gives much better results. The MAP curves match the data more
closely for only a slight increase in the number of parameters. A summary of
the AIC results is shown in table 3.15. We conclude that although the AIC is
lowest for the different variances model, it is not a large amount lower than
the AIC for the simpler offset peaks model for either dataset when compared
with the reductions for the previous model alterations. To model the data we
should use offset peaks with different variances.
cancer melanoma
AIC BIC # parameters AIC BIC # parameters
single -2,594,632 -2,343,817 20,044 -5,576,214 -5,278,873 23,110
double -3,090,994 -2,591,523 39,916 -5,725,350 -5,132,598 46,070
offset -4,283,938 -3,782,705 40,056 -6,181,296 -5,587,103 46,182
variance -4,296,174 -3,793,243 40,192 -6,200,348 -5,604,714 46,294
Table 3.15: The AIC and BIC statistics for the four models considered in this
chapter.
For comparison we will now also consider the BIC statistics. From the BIC
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results we see that, in agreement with the previous conclusions using AIC,
the model including offset peaks with differing variances is deemed to be the
most suitable. When moving from the single peaks to the double peaks model,
the BIC heavily penalised the introduction of nearly double the number of
parameters for the melanoma dataset which led to an increase in the statistic.
However, when the more complex models were analysed the BIC statistic fell
again.
In this chapter we split the datasets into sections and model each of the sec-
tions separately. This resulted in having around 20 different estimates for the
proportionality constant ξ - one in each section instead of the overall parame-
ter that we would prefer to model. When checking the values of ξ obtained for
each section it was found that, for all sections that contained visible peaks, the
value of ξ converged to roughly the same value in each section. For the sections
without visible peaks the value of ξ was larger but the peaks had negligible
height. It seems reasonable to assume that the value of ξ is approximately
constant over all sections.
The analysis of the breast cancer and melanoma datasets using the MCMC
methods discussed in this chapter requires a large amount of computational
time. This is primarily because each section of the data must be run sequen-
tially so as not to split processor time between tasks. The High Performance
Computing (GRID) system was used to compare the times taken to analyse the
datasets. Using a desktop computer to carry out the analysis of the complete
datasets resulted in total analysis times of 563.5 minutes and 706.5 minutes for
the breast cancer and melanoma datasets respectively. When using the GRID,
the time taken for the analysis of each section of data was reduced by approx-
imately 25% in both datasets. However, since there are multiple processors on
the GRID, each section of the data can be submitted to a different one and the
analysis carried out in parallel. This reduces the time taken for each dataset
to the time taken for the largest section. The times taken when running the
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analysis in parallel are 74.9 minutes and 78.4 minutes for the breast cancer
and melanoma datasets respectively.
In Dryden et al. (2005) the breast cancer dataset was analysed using a
variant of the Hotelling T 2 test (Hotelling, 1931). The day information can be
taken into account when using the Hotelling test as vectors can be constructed
of the peak heights over all four days. A brief description of the technique now
follows.
Let x¯Ai and x¯Bi be the q-vectors of means in groups A and B respectively
at m/z value i (i = 1 . . . p), with sample sizes nA, nB. Let Sxi be the unbiased
pooled within-group q × q covariance matrix at m/z value i. For the breast
cancer data q = 4 as there are 4 days of information available and p = 13951
is the number of recorded m/z values between 2000 and 30,000 Da. The two
sample Hotelling T 2 test of H0 : µAi = µBi versus H1 : µAi 6= µBi at m/z value
i is T 2x,i = (x¯Ai − x¯Bi)TS−1xi (x¯Ai − x¯Bi) under certain assumptions (see Dryden
et al., 2005) and we reject H0 in favour of H1 at the 100α% level if
T 2x,i > Tcrit(α) =
(nA + nB)(nA + nB − 2)q
nAnB(nA + nB − q − 1) Fq,nA+nB−q−1(1− α)
where Fν1,ν2(1− α) is the 1− α quantile of the Fν1,ν2 distribution.
The Dryden et al. (2005) method tries to account for the extra noise
which would be inherent in further repetitions of the experiment. The noise
is considered to be iid Gaussian with mean zero and variance σ2 and thus the
unobserved noisy vector wi = xi + ǫi where ǫi ∼ Nq(0, σ2Iq) independently.
The offset test statistic is then T 2i (σ
2) = (x¯Ai− x¯Bi)T (Sxi+σ2Iq)−1(x¯Ai− x¯Bi).
Given σ2, T 2i (σ
2) can be observed and these statistics can be used for inference.
A suitable value of σ2 is determined by a calibration method and subsequently
H0 is rejected if T
2
i (σ
2) > Tcrit(α).
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The significant results obtained from this analysis are shown in table 3.16.
When comparing these results with the MCMC result tables presented in this
chapter we see that most of the values in table 3.16 are identified by the MCMC
method. The exceptions are the rows including 7,687 Da, 11,381 Da and 15,377
Da for the control/treated comparisons and the rows including 6,231 Da, 6,552
Da, 10,169 Da and 13,811 Da for the control/control comparisons.
adc/adt tdc/tdt mcc/mct adc/tdc adc/mcc tdc/mcc
3839
4127 4120
4396 4396
4648
4813 4798
5364
5692 5653 5661
6231 6282
6552 6552
7029 7017 7019
7687 7685
8094
10169
10265 10248
11381 11351 11369 11340
13854 13811 13831
14028 14048 14055
15377 15390 15402
Table 3.16: Significant m/z values in the breast cancer dataset from Dryden
et al. (2005). Similar values are listed on the same line.
There are some differences between the results from the two methods. In
the MCMC analysis the significant result at 7,029 Da is between mccon and
mctax - in table 3.16 it is between the adcon and adtax groups. Also the last
row in table 3.16 shows differences with adc/tdc and adc/mcc - in the MCMC
analysis the difference at this m/z value is with tdc/mcc comparison.
It should be noted that the Hotelling analysis does not reveal any signifi-
cant differences between any of the spectra for m/z values higher than 15,500
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Da. The MCMC approach provides many such m/z values of which the ma-
jority are for mcc/mct and tdc/mcc comparisons.
In Mian et al. (2003) the breast cancer dataset was studied using artificial
neural networks (ANNs). This research highlighted the m/z values 10,518 Da,
11,100 Da, 11,687 Da and 13,239 Da as showing good classification ability be-
tween control and treated cell-lines. Only m/z values between 10 kDa and 15
kDa were considered in that analysis. The models described in this chapter do
not reproduce any of these results. However, since the work was investigating
classification and we are testing for significance one may expect different con-
clusions.
In Mian et al. (2005) the melanoma dataset was studied using ANNs. They
find that there was a large difference between stage I and stage IV melanoma
at 11,700 Da in terms of the variability between the two groups at this m/z
value. The models used in this chapter do identify this m/z value as one ex-
hibiting differences between the two groups.
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Chapter 4
Applying Multilevel Modelling
to Proteomic Mass
Spectrometry Data
4.1 Introduction
In section 1.5 an overview of some multilevel modelling techniques was pre-
sented. This chapter will consider the use of this framework to model the
available datasets via the use of mixed effect models. Inference will be carried
out using the software package MLwiN (Rasbash et al., 2000). The construc-
tion of the model will be described in section 4.2 and the results obtained
from the analysis are described in section 4.3. A series of related models are
considered and the results are compared with those from the MCMC analysis
presented in chapter 3.
4.2 The Model
One of the main aims of this thesis is to identify locations along a spectrum
which enable us to differentiate between drug-treated breast cancer cell-lines
and non-treated controls and to differentiate between stage I and stage IV
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melanoma. In this chapter we aim to find these locations by considering a
multilevel model for the data. Multilevel modelling is a useful technique to
apply when the data have an obvious hierarchical structure such as here where
we have m/z values within spectra.
4.2.1 Model Summary
In chapter 3 the data were considered as a mixture model of Gaussian peaks.
The initial model used was yis ∼ N(θis, τ−1) where θis is
θis =
k∑
j=1
hjs(ξµ
2
j)
− 1
2 exp
(
−1
2
(ξµ2j)
−1(xi − µj)2
)
. (4.1)
The index i = 1, . . . , p represents the position on the spectrum, xi is the i
th
m/z value, s = 1, . . . , n is the spectrum number, j = 1, . . . , k is the peak
number, ξ is the constant of proportionality and µj are the peak locations.
A more complex model was then introduced which considered each peak
in the data as a combination of two peaks - one spiky peak as already mod-
elled and another with a larger variance to accommodate a baseline amount
of intensity. This larger variance was set to be twice the variance of the spiky
peak. Offset peaks were also considered in a third model which resulted in
better matching to the data for asymmetrical peaks. The equation for θis for
the double and offset peaks models is
θis =
k∑
j=1
hjs(ξµ
2
j)
− 1
2 exp
(
−1
2
(ξµ2j)
−1(xi − µj)2
)
+
k∑
j=1
h∗js(ωjξ(µj + δj)
2)−
1
2 exp
(
−1
2
(ωjξ(µj + δj)
2)−1(xi − (µj + δj))2
)
(4.2)
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where i, xi, s, n, j, ξ and µj are as in equation (4.1), the δj parameters model
the offset of the second peaks from the main location µj (set to zero for the
double peaks model) and the ωj are the variance scaling factors for the double
peaks. For the double peaks and offset peaks models these ωj were set to 2. A
final extension of the model considered the possibility that the variance scaling
parameters ωj were different for each peak.
4.2.2 The Multilevel Model
In the two datasets to be analysed there exists a two-level structure - m/z
values within spectra. As shown in section 1.6.3 a multivariate normal model
is of the form y ∼MVN(Xβ,V) and for two-level models this can be rewritten
as
yij = X
T
ijβ + Z
T
ijuj + eij
uj ∼MV N(0,Ωu) , eij ∼ N(0, σ2e)
where i indexes m/z value and j indexes spectrum in our example. The value
of y is the observed datapoint at m/z value i in spectrum j, β and u are
vectors of parameters, the matrix X is the design matrix for the fixed effects
and the matrix Z is the design matrix for the random effects. The uj and the
eij are independent. Such a model is called a linear mixed effect model.
As discussed previously the main points of interest in the data are the
location and height of peaks and from this information we wish to discover
where the groups are different. We can accommodate this requirement in
the model by fitting a common fixed effect for each peak in each group to
represent an average intensity. Differences in the fixed effect estimates will
show any locations with significant differences in peak height between groups.
Incorporating random effects for each peak in each spectrum will better match
the fitted model to the data.
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Due to computational limitations, inference on the full dataset is difficult
in MLwiN. In order to analyse the data we must therefore consider using the
splitting algorithm described in section 3.2.6 which creates a partition of the
available m/z values into a number of sections. We obtain 17 sections for the
breast cancer dataset and 19 sections for the melanoma dataset.
We now describe how to create the fixed and random predictors used in
the initial model of equation (4.1). This model does not involve the presence
of multiple peaks at each location. Firstly the peak finding method described
in chapter 2 is used to obtain 150 peak locations across the whole dataset. For
each section of data the relevant peak locations are selected in order from this
list so that they are in order of decreasing peak size. Consider a section of the
data of length t with p relevant peak locations. For the first peak location, µ1,
identified in this section by the algorithm we construct a peak at this location
from the equation
θi = (ξµ
2
1)
− 1
2 exp
(
−1
2
(ξµ21)
−1(xi − µ1)2
)
(4.3)
where the index i = 1, . . . , t represents the position on the spectrum, xi is
the ith m/z value and ξ is the constant of proportionality. The value of ξ is
obtained from the MCMC analysis in chapter 3.
We now create from this the design matrices for the X and Z predictor
variables associated with the first peak location. The random predictor con-
sists of n replicates of this first fitted peak where n is the number of spectra in
the dataset. If there are g groups in the dataset (6 for the breast cancer and
2 for the melanoma) then we also create g fixed predictors for this first peak.
The parts of the fixed and random design matrices relevant to the first group
are identical. The fixed predictors for the remainder of the groups indicate
where we wish to measure differences from the first group. Fixed and random
predictors should be created this way for each of the peak locations identified
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by the algorithm. For an example structure diagram for the fixed effect matrix
see figure 4.1. In this figure we have a dataset containing three spectra - one
in each of three groups - and two peak locations, the second earlier (in m/z
terms) than the first.
Figure 4.1: Diagram showing the general structure of the fixed effects design
matrix X. The matrix is of dimension 3t × 3p. The areas of white contain
zeros and the gradient of grey represents the slopes of the peak. The top of
the peak is indicated by black.
For the breast cancer dataset we have 144 spectra in 6 groups so the dimen-
sion of the fixed effect design matrix X is 144t×6p where t is the length of the
section of data and p is the number of peaks fitted. The respective dimension
for the melanoma dataset is 205t× 2p.
For the more complex models we calculate additional fixed and random
effects using the same method. These extra effects are to model the presence
of the double peaks at each location. For the jth peak location we construct
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the peak using the equation
θis = (ωjξ(µj + δj)
2)−
1
2 exp
(
−1
2
(ωjξ(µj + δj)
2)−1(xi − (µj + δj))2
)
(4.4)
where, in addition to the parameters in equation (4.3), δj models the offset of
the double peak from the original location (zero for the double peaks model)
and ωj models the scaling parameter for the double peak variance (2 for the
double and offset peaks models).
In summary, if the total number of peaks fitted in the model is p and the
number of spectra in the dataset is n then the model becomes
Y
nt×1
= X
nt×gp
β
gp×1
+ Z
nt×pn
U
pn×1
+ E
nt×1
U ∼MV N(0,Ωu) , E ∼ N(0,Ωe).
The vector Y is the vector obtained by stacking the spectra one by one into
a single column and the vector E is the stacked error vector. The first column
of the fixed effect design matrix X consists of n replicates of the first fitted
peak. The second column to the gth column, where g is the number of groups,
consist of replicates of the first fitted peak when the corresponding points in
the Y vector are in groups 2, . . . , g and zero otherwise. This pattern repeats
in the next columns of X for other peaks in the model. The random effects
design matrix Z is similar to the fixed effects design matrix X except we do
not distinguish between groups. However, we do distinguish between spectra
and a different random effect will be obtained for each spectrum. Therefore
the ith column of the Z matrix consists of n replicates of the ith fitted peak.
The model parameters β and U are estimated by using an iterative pro-
cedure, namely the iterative generalised least squares (IGLS) algorithm as
described in section 1.6.4.
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4.2.3 The Shifting Procedure
The peak finding procedure from chapter 2 finds a series of locations where
Gaussian peaks can be placed which allow us to obtain a quick approximation
of the data. However, we found in chapter 3 that the locations obtained from
this algorithm may not be ‘optimal’ in the sense that the model deviance could
be decreased by adjusting the peak locations.
To reduce the deviance for the mixed effect models investigated in this
chapter we can consider shifting the location of a peak by one recorded m/z
value at a time in either direction until we reach a local minimum deviance.
This involves the recalculation of the design matrices X and Z. If the deviance
increases after the first shift we should instead consider moves in the opposite
direction until we reach the local minimum. This procedure should be used
on each of the peaks in the model. Every time a peak is moved the fixed and
random predictors associated with that peak will need to be recalculated.
For the case where two or more peaks are close together we should repeat
the procedure on these peaks. It is possible that, after moving the first peak,
the movement of the second one has an effect on the best location for the first.
After all the peaks have been moved once we should check that we cannot
decrease the deviance further by making extra changes. If peaks are far apart
then this second round of checking should not be required.
4.3 Application to Datasets
4.3.1 Results for the Breast Cancer Dataset
Firstly the IGLS algorithm was run to get estimates for each of the fixed and
random effects and the variances Ωu and σe using the 150 peaks obtained from
the peak finding algorithm. To try and improve the fit of the model the shift-
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ing procedure described in section 4.2.3 was used. The first peak was moved
one m/z value at a time to the left or right until the deviance did not decrease
further. This procedure was repeated for all of the peaks in the model. After
carrying out this shifting it appeared that the peaks had moved to locations
similar to those obtained from the MCMC analysis in chapter 3.
In figure 4.2 the original data from 7,600 Da to 8,200 Da are shown along
with the fixed effects which model the average spectrum for the groups. The
black line shows the fixed predictor under the single peaks model and the blue
line shows the fixed predictor under the model where the double peaks can
have offset peaks and differing variances. The change in fit is most obvious for
the peak around 8,100 Da. Here the peak is non-Gaussian and the increase
in model complexity has allowed the model to better fit the peak shape. In
the groups adcon, tdcon and tdtax there there are two obvious peaks present
between 7,800 Da and 8,000 Da. The fixed effect in these groups changes
to model the data more accurately. The peak at 7,700 appears to be fairly
symmetric so the fixed effect does not change greatly between the two models
shown.
To determine whether any of the peaks could be removed from the model
Z-tests were calculated at the 5% level. If the fixed effects for a peak were
insignificant for all of the six groups then the peak was removed. This resulted
in 22 peak locations being omitted which leaves 128 to model the presence of
a peak in any of the six groups.
These 128 remaining locations at which a peak was present were further
checked to identify where the fixed effects significantly differed between groups.
As in chapter 3 we need to correct for the large number of tests being carried
out. This was achieved by using the false discovery rate algorithm described
in section 1.6.6 with q∗ = 0.05. Following this procedure, forty five peaks were
deemed significant for one or more of the control/control comparisons and their
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Figure 4.2: Plots of the breast cancer data with the fixed effects under the
single peaks model (black) and the differing variance model (blue).
locations are shown in table 4.1. Thirty peaks were significant for one or more
of the control/treated comparisons and their locations are shown in table 4.2.
From table 4.2 it can be seen that there are some differences identified between
the two chemoresistant groups adcon and adtax. The treatment should have no
effect on these cell lines. Also only one location was identified in the MCMC
analysis in chapter 3 which exhibited differences between these two groups.
However, in chapter 3 the tests for significance were separated by day and
this information was not considered in the multilevel framework considered
in this chapter. This may explain some of the differing results between the
approaches.
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m/z 2226 2426 2724 2954 3584
groups AM AT,TM AT,AM TM AM,TM
m/z 3709 4019 4229 4329 4389
groups TM AT,TM AT AT AM,TM
m/z 4641 4703 4803 4887 5103
groups AM,TM AM,TM AM,TM TM AT,TM
m/z 5376 5553 5669 6566 7019
groups AT,TM AT AT,AM AT AT
m/z 7146 7274 7694 7939 8110
groups AT,TM AT AT,AM AT AM
m/z 8212 9187 9651 10115 10230
groups AT TM TM TM AT,TM
m/z 10435 10888 11137 11357 11918
groups AM,TM AT AT,AM AT AT,AM
m/z 12643 13432 14046 14250 14857
groups AM AT AT AT AT,TM
m/z 15402 16315 17764 20360 26743
groups TM AT AT,TM AT AT
Table 4.1: The peak locations in the breast cancer dataset with sig-
nificant differences between adcon/tdcon(AT), adcon/mccon(AM) and td-
con/mccon(TM).
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m/z 2186 2687 3590 4391 4703
groups T,M T,M M T T
m/z 5406 6693 7019 7694 8110
groups A,M T M A A,M
m/z 8473 8769 10228 10426 11718
groups T M M M A,T
m/z 12643 13432 14046 14857 15043
groups A,M A M M T
m/z 15402 16315 17983 19030 20010
groups M A T M A,T
m/z 20815 21010 23083 25373 26743
groups M A T M A
Table 4.2: The peak locations in the breast cancer dataset with significant
differences between adcon/adtax(A), tdcon/tdtax(T) and mccon/mctax(M).
The fixed effect parameters for the adcon group appeared to be larger than
for the other groups at most peak locations. One notable exception occurs
at an m/z value of 4,389 Da. This location had two of the most significant
differences between groups of all the peaks modelled. These occurred between
the adcon and mccon groups and between the tdcon and mccon groups. Plots
of the original data around this m/z value are shown in figure 4.3. Also highly
significant were the peaks at m/z values of 10,231 Da and 10,425 Da. At both
of these locations the difference lies between the tdcon and mccon groups.
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Plots of these m/z values are shown in figure 4.4.
The locations 4,389 Da and 10,231 Da identified here as exhibiting some of
the most significant differences between groups were also identified as the same
in the MCMC analysis presented in chapter 3. In addition they were identified
in the classification analysis presented in chapter 2 as being some of the best
classifiers of new spectra. The remainder of the top ten most significant loca-
tions identified by the multilevel analysis also appear in the MCMC analysis
results shown in tables 3.4 and 3.5 but not in the classification results. This
lack of similarity should not be unexpected as we are examining classification
in chapter 2 and identifying differences in chapter 4.
For the MCMC analysis we concluded that it was important to consider the
peaks as a combination of two offset peaks with different variances as the AIC
statistic was lowest for this model. We can incorporate this into the multilevel
model by changing the fixed and random effects appropriately. For each of the
three more complex models (double peaks, offset peaks and differing variance
peaks) the number of fixed and random effects will double compared with the
original model to accommodate the parameters for the peaks with larger vari-
ances.
In figure 4.5 the estimates of the data are shown for each of the four models
considered in this chapter for the m/z values between 7,400 Da and 8,400 Da.
The data are reflected in the x-axis for comparison. The single peaks model is
represented by the red curve, the double peaks model by the black curve, the
offset peaks model by the green curve and lastly the differing variances model
by the blue curve.
At 8,100 Da and 7,950 Da the fit to the data improves as the complexity
of the model increases, with the blue curve providing a visibly better match.
At around 8,050 Da moving through the four models (red to blue) allows the
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Figure 4.3: Plots of the original data around the m/z value 4,389 Da separated
by group.
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Figure 4.4: Plots of the original data around the m/z values 10,231 Da and
10,425 Da separated by group.
140
4.3 Application to Datasets
7600 7700 7800 7900 8000 8100 8200
−
4
−
2
0
2
4
mz value
in
te
ns
ity
Figure 4.5: The estimates obtained for one spectrum from the single(red),
double(black), offset(green) and differing variance(blue) models as compared
to the original breast cancer data (reflected in the x axis).
lowest point between the two peaks to be reduced. Modelling using offsets
(green and blue) has allowed the non-symmetric peak at 8,050 Da to be more
closely modelled and also the peak at 7,700 Da to move to the left resulting
in a better fit to the data. The deviances associated with the four models are
shown in table 4.3.
The single peaks and double peaks models are nested and so a likelihood
ratio test can be calculated to determine which of the two models is preferable.
The number of parameters is increased by 896 when moving to the double peaks
model and these parameters consist of 768 extra fixed effects and 128 extra
141
4.3 Application to Datasets
model
single double offset variance
deviance -1,259,241 -1,563,974 -1,796,832 -1,921,647
Table 4.3: The deviances for the four models of the breast cancer data consid-
ered in this chapter.
variances. The test is thus
−1, 259, 241− (−1, 563, 974) = 304, 733 >> χ2896,0.95 = 966.8
and the double peaks model is a significant improvement on the simpler model.
The offset and differing variances models are not nested and so likelihood ratio
tests cannot be used. However, the AIC and BIC statistics can be calculated
and are shown in table 4.4. The number of parameters does not change after
the double peaks model and so we find that the the model considering peaks
with differing variances is the most preferable as it has the lowest deviance.
model
single double offset variance
AIC -1,257,449 -1,560,388 -1,793,246 -1,918,061
BIC -1,246,237 -1,537,951 -1,770,809 -1,895,624
Table 4.4: The AIC and BIC statistics for the four models of the breast cancer
data considered in this chapter.
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4.3.2 Results for the Melanoma Dataset
Before starting the multilevel analysis the peak finding algorithm from chap-
ter 2 was implemented to obtain 150 peak locations across the entire dataset.
These locations were used to create the fixed and random predictor matrices
and the IGLS algorithm was then used to obtain estimates for the effects and
the variances Ωu and σe for each section of the data. Using the shifting proce-
dure described in section 4.2.3, each peak was moved one m/z value at a time
to the left or right in order to minimise the deviance of the model. This pro-
cedure was repeated for all of the peaks in the model and, after the procedure
was completed, the peaks had moved to locations similar to those obtained
from the MCMC analysis in chapter 3.
In figure 4.6 the original data from 7,400 Da to 8,500 Da are shown along
with the fixed effects which model the average spectrum for the groups. The
black line shows the fixed effect under the single peaks model and the blue
line shows the fixed effect under the model where the double peaks can have
differing variances. The change in fixed effect is most obvious in the stage I
plot. As the peak at 7,800 Da is non-symmetric, the addition of peak offsetting
has enabled the fitted peak to change shape to better match the original data.
The peak height in stage IV remains roughly the same although the location
changes, whereas both the height and location change in stage I.
To determine whether any of the peaks could be removed from the model
Z-tests were calculated at the 5% level. If the fixed effects for a peak were
insignificant for both stage I and stage IV then the peak was removed. This
resulted in 46 peak locations being removed which leaves 104 to model the
presence of a peak in one or both of the groups. These remaining locations were
studied to identify where the fixed effect in stage I was significantly different to
that in stage IV. After correcting for multiple testing using the false discovery
rate algorithm in section 1.6.6, forty peaks were deemed significant and their
locations are shown in table 4.5 along with the associated values of the Z
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Figure 4.6: Plots of the melanoma data with the fixed effects under the single
peaks model (black) and the differing variance model (blue).
statistic. From table 4.5 it can be seen that the fixed effect parameters for
stage IV generally appeared to have lower values than their counterparts in
stage I. There are only 3 m/z values where the peaks have larger magnitude
in stage IV - 6,754 Da, 11,524 Da and 11,705 Da. For the two peaks in the
11,600 Da area the fixed effect in stage I is deemed not significantly different
to zero and so these locations refer to peaks only present in stage IV. For the
peak at 6,754 Da the fixed effects in both groups were significantly different to
zero and thus there is a peak present in both groups. The original data at the
two m/z values around 11,600 Da are shown in figure 4.7 showing the obvious
difference between stage I and stage IV.
144
4.3 Application to Datasets
m/z 2227 2312 2489 2535 2729
Z statistic -8.250 -6.000 -8.333 -5.167 -6.000
m/z 2777 2960 3065 3304 3552
Z statistic -6.333 -8.333 -8.250 -5.889 -6.667
m/z 3891 3972 4477 4653 4777
Z statistic -8.833 -4.545 -4.333 -5.000 -5.250
m/z 6452 6650 6754 7571 7671
Z statistic -5.890 -5.532 6.469 -8.000 -7.538
m/z 7789 7986 8156 8364 8931
Z statistic -7.438 -5.690 -5.606 -5.000 -4.750
m/z 9323 9481 9672 11524 11705
Z statistic -4.941 -5.452 -4.500 5.636 5.469
m/z 13943 14210 14655 17235 17424
Z statistic -5.147 -7.230 -6.000 -4.688 -5.200
m/z 17811 18206 28170 28742 29239
Z statistic -5.143 -4.750 -7.543 -7.125 -6.600
Table 4.5: The peak locations with significant Z statistics between the two
stages of melanoma.
145
4.3 Application to Datasets
11000 11500 12000 12500
0
15
30
Stage I
m/z value
in
te
ns
ity
11000 11500 12000 12500
0
15
30
Stage IV
m/z value
in
te
ns
ity
Figure 4.7: Plots of the melanoma data at the peak locations where the stage
IV intensity is higher than in stage I.
In chapter 3, considering the peaks as a combination of two offset peaks
with different variances was deemed important because this model had the
lowest AIC statistic. By changing the fixed and random predictors appropri-
ately this structure can be incorporated into the multilevel model. For each of
the three more complex models (double peaks, offset peaks and differing vari-
ance peaks) the number of fixed and random effects increases from 208 and
104 respectively under the single peaks model to 416 and 208 to accommodate
the parameters for the peaks with larger variances.
In figure 4.8 the estimates of the data are shown for each of the four models
considered in this chapter for the m/z values between 7,400 Da and 8,400 Da.
The data are reflected in the x-axis for comparison. The single peaks, double,
offset and differing variances models are respectively represented by the red,
black, green and blue curves.
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Figure 4.8: The estimates obtained for one spectrum from the single(red),
double(black), offset(green) and differing variance(blue) models as compared
to the original melanoma data (reflected in the x axis).
At 7,800 Da and 8,150 Da increasing the complexity of the model provides
a much better fit to the data, with the blue curve showing the best match of the
four models. At around 7,950 Da moving from the single to the double peaks
model (red to black) allows the peaks to be modelled more closely because of
the reduction in the ξ parameter. In that area there are now troughs present
instead of just an overall curve as there was under the single peaks model.
Although the second peak around 7,950 Da is modelled more closely with the
black curve the first peak in that area is not fitted well. When the additional
complexity of the offset peaks and different variances is implemented the fit is
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much improved. The deviances associated with the four models are shown in
table 4.6.
model
single double offset variance
deviance -2,228,228 -2,527,056 -2,801,919 -2,980,246
Table 4.6: The deviances for the four models of the melanoma data considered
in this chapter.
Since the single peaks and double peaks models are nested, we can carry
out a likelihood ratio test to determine which of the two models is preferable.
The number of parameters is increased by 312 when moving to the double
peaks model (208 extra fixed effects and 104 extra variances) and thus the test
is:
−2, 228, 228− (−2, 527, 056) = 298, 828 >> χ2312,0.95 = 354.2
and the double peaks model is thus a significant improvement on the simpler
model. Likelihood ratio tests cannot be used for further model comparisons
as the offset and differing variances models are not nested. Using the model
deviances and the AIC/BIC statistics shown in tables 4.6 and 4.7 we consider
the differing variances model to be the most preferable as it has both the low-
est deviance and the lowest AIC/BIC.
model
single double offset variance
AIC -2,227,602 -2,525,806 -2,800,669 -2,978,996
BIC -2,223,574 -2,517,764 -2,792,627 -2,970,954
Table 4.7: The AIC and BIC statistics for the four models of the melanoma
data considered in this chapter.
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4.4 Summary
In this chapter we have shown how multilevel modelling techniques can success-
fully be used to model mass spectrometry data. The peak finding procedure
from chapter 2 is used to provide a suitable starting point for the fixed and
random predictors. These predictors are then shifted by one recorded m/z
value at a time in order to minimise the deviance of the model. Using mixed
effect models means that the data are described using a much smaller number
of parameters than there are original datapoints.
In agreement with the results from chapter 3 it has been shown that it is
important to consider the data not as a combination of single peaks but as
a combination of double peaks with offset locations. Using likelihood ratio
tests where applicable and AIC/BIC calculations otherwise it has been shown
that using the model allowing offset peaks with different variances gives much
better results than the simpler models. By doubling the number of parameters
in the model we obtain a much better match to the data. A summary of the
model deviances and AIC/BIC statistics are shown in table 4.8. We conclude
that the most complex of the four models is the most preferable.
cancer melanoma
deviance AIC BIC deviance AIC BIC
single -1,259,241 -1,257,449 -1,246,237 -2,228,228 -2,227,602 -2,223,574
double -1,563,974 -1,560,388 -1,537,951 -2,527,056 -2,525,806 -2,517,764
offset -1,796,832 -1,793,246 -1,770,809 -2,801,919 -2,800,669 -2,792,627
variance -1,921,647 -1,918,061 -1,895,624 -2,980,246 -2,978,996 -2,970,954
Table 4.8: The deviances and AIC/BIC statistics for the four models consid-
ered in this chapter.
It should be noted that there are other hidden parameters in the multilevel
models considered in this chapter, for example, the proportionality constant ξ
which models the fact that the peak width increases with the m/z value and
the peak locations µj. However, the model deviances are so large compared
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with the number of hidden parameters that even if they were included the
overall conclusions would remain the same.
When comparing the m/z values obtained from this analysis which exhibit
different intensities between the groups with those from the MCMC analysis
presented in chapter 3 we see that there are great similarities. The majority
of the peak locations still indicate that the peak heights are lower in stage
IV than in stage I. For both datasets the locations exhibiting significant dif-
ferences between groups remain similar across the two analyses in chapter 3
and this chapter. In the breast cancer dataset the numbers of significant loca-
tions for the control/control comparisons are 40 and 45 for chapters 3 and 4
respectively. For the control/treated comparisons the corresponding number
of significant locations is 30 in both chapters. For the melanoma dataset the
numbers of significant locations remain similar between the two analyses at 40
and 41 respectively. However, for the breast cancer dataset there are a greater
number of differences identified between the adcon and adtax groups in the
multilevel analysis than in the MCMC analysis. This may be attributable to
the omission of day information in the multilevel analysis.
The results obtained by Dryden et al. (2005) and Mian et al (2005) are also
found in the multilevel analysis. In Dryden et al. (2005), however, no signifi-
cant results are found at m/z values greater than 15,000 Da. In this chapter
there are numerous examples. The number of significant results obtained may
have been affected by small sample sizes and if more data was available the
number may be reduced. Mian et al (2005) identified the m/z value 11,701
Da as a location where the two groups have highly different variability. This
location is identified in the multilevel analysis as one where the two groups
differ.
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Conclusions and Further Work
5.1 Conclusions
The two main objectives of this thesis were to model the spectra obtained
from SELDI-TOF mass spectrometric analysis of cancerous cells and sera and
to identify where significant differences in protein expression levels occurred
between groups. This has involved the use of existing statistical techniques
along with the development of a procedure to identify peaks present in the
data.
The data obtained from mass spectrometry of proteins is high-dimensional
in nature and thus the first task was to reduce the dimensionality of the prob-
lem. This was achieved in chapter 2 with the development of a peak finding
algorithm. The algorithm worked by identifying the largest peak in the mean
spectrum and fitting a Gaussian peak to this location with heights that differ
between spectra to match the data. The effects of this peak are then subtracted
from the data and the process repeated on the remaining data until a specified
number of peaks have been fitted. By using this algorithm to identify peaks in
the data we reduced the number of m/z values needed to describe a spectrum
from ≈ 14, 000 to 150. Despite this 100 fold reduction, the ability to classify
test spectra given a set of training spectra did not fall greatly. When the
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complete spectra were used, correct classification rates of 89% and 86% were
obtained when using principal components analysis combined with linear dis-
criminant analysis for the breast cancer and melanoma datasets respectively.
After dimension reduction using the peak finding algorithm instead of principal
components analysis, the respective correct classification rates were 84% and
81%. The maximal correct classifications when using the algorithm each used
around 30 peak locations whereas information from all 14,000 m/z values was
used to obtain the higher rates. Classification using peak locations provides
us with much more interpretable reasons for classifying a particular spectrum
into a group than when using the principal components. We can identify a
particular m/z value which classifies well and then molecules around this m/z
value can be further investigated by chemists to determine if they hold any
potential information for drug development.
Methods were also developed in chapters 3 and 4 to determine where sig-
nificant differences in protein expression levels occurred between groups. In
chapter 3 the use of Markov chain Monte Carlo methods enabled a parametric
model to be fitted to the data. The model parameters initially included peak
locations, peak heights, a proportionality constant used to calculate the peak
variances and a residual variance/precision parameter. The parameters were
all updated using Metropolis-Hastings steps with normal proposal distributions
with the exception of the residual variance parameter which was updated us-
ing a Gibbs sampling step. The likelihood expression was complex and the
full conditional distribution could only easily be written down for the residual
variance parameter. An adapting stage was built into the MCMC algorithm to
fine tune the proposal variances so that the proposals were accepted between
40% and 60% of the time. The peak finding procedure from chapter 2 was
used at the beginning of the MCMC algorithm to provide a suitable starting
point for each of the chains. This helped to ensure that prominent peaks in
the data were not missed by a bad choice of starting value. The model was
extended via three more related models to include a combination of two offset
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peaks with different variances at each peak location. This model provided a
better fit to the data than the initial model and a selection of m/z values were
identified which exhibit differences between groups. The m/z values identified
by this MCMC analysis showed similarities to those obtained by Dryden et al.
(2005). It was also shown in chapter 3 that by using parallel processing on
the GRID computing system we can greatly reduce the computational time
needed to carry out MCMC analysis of the data.
An algorithm was developed to create a partition of the data so that each
section could be modelled separately. The split points were placed at m/z
values with low average intensity in an attempt to not split peaks across sec-
tion. Using this algorithm on the two datasets resulted in 17 sections for the
breast cancer and 19 for the melanoma. This partition was used for both the
MCMC work and the multilevel modelling work to reduce computation time.
The methods used in chapters 2 and 3 do not take into account the complete
structure of the data. To incorporate this hierarchical structure in the data
a multilevel modelling framework was used in chapter 4. Using the IGLS al-
gorithm to estimate the parameter values a mean spectrum for each group
was identified and differences in these mean spectra were calculated using ap-
proximate Z tests. The four models used for the Bayesian analysis were also
considered here and the most appropriate model was determined by likelihood
ratio tests and AIC statistics. In agreement with the Bayesian analysis it was
found that the model consisting of offset peaks with differing variances was
considered the most appropriate.
In summary, the overall results obtained from this research are shown in ta-
bles 5.1 and 5.2. These tables show the m/z values which have been identified
as being important in differentiating between different groups. Only the most
significant result for each m/z value is shown. At 5,416 Da both the mcc/mct
and adc/adt comparisons are significant in the MCMC and multilevel analyses
but the comparison with the largest statistic has changed between chapters.
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Similar reasoning applies to the location at 8,110 Da.
m/z value 4,393 4,881 5,416 7,453 8,110 10,230
% times one of top
6 best classifiers 31.9 19.1 39.3 61.0 83.2 24.6
(chapter 2)
largest t statistic -8.576 -8.803 8.713 12.852 9.219 5.408
between groups adc/mcc tdc/mcc mcc/mct adc/tdc mcc/mct tdc/mcc
(chapter 3) (3) (3) (4) (3) (4) (2)
largest Z statistic
between groups 14.800 11.318 6.068 11.290 9.891 13.102
(chapter 4) adc/mcc tdc/mcc adc/tdc adc/tdc adc/mcc tdc/mcc
Table 5.1: m/z values identified as important in the analyses between groups
in the breast cancer dataset.
m/z value 2,495 2,771 3,316 3,885 8,949 28,160
% times one of top
6 best classifiers 15.1 16.1 17.3 97.1 16.5 31.0
(chapter 2)
t statistic
between stages 7.885 6.471 4.171 9.085 4.845 7.566
(chapter 3)
Z statistic
between stages 8.333 6.333 5.889 8.833 4.750 7.543
(chapter 4)
Table 5.2: m/z values identified as important between stages in the melanoma
dataset.
These m/z values should be investigated more thoroughly to identify pre-
cisely which molecules are present at these locations. These molecules could
then be studied to ascertain if they show any promise for drug development.
The work in this thesis has considered a variety of ways to analyse mass
spectrometry data. There remain, however, many ways in which the methods
currently in use could be improved. Some potential improvements are dis-
cussed in the next section.
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5.2.1 Different distributions for peaks
The model that has been developed in this thesis for proteomic spectra con-
sists of a mixture of Gaussian peaks at differing locations along a spectrum. In
chapter 3 it was noted that some of the peaks in the data do not appear to be
Gaussian and that a large number of peaks appear to have longer right hand
tails. This is a more obvious problem with the melanoma data although it
does sometimes occur in the breast cancer data. The work presented in chap-
ter 3 attempted to reduce this problem by considering the modelled peaks as a
combination of two offset peaks with differing variances. This solution allowed
the modelling of the longer right hand tails although, in some cases, the peak
heights did not match the data exactly.
Another possible way to model the data would be to use other distributions
for the peaks. Three possibilities are the lognormal, beta or gamma distribu-
tions and an example of each is shown in figure 5.1. When the parameter
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Figure 5.1: Plots of the lognormal, gamma and beta distributions showing how
certain parameter values could be chosen to model non-Gaussian peaks.
values are changed then the peaks can appear more symmetrical. This could
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prove useful in a dataset such as the breast cancer dataset studied in this
thesis where there are a combination of symmetric and non-symmetric peaks.
In the MCMC algorithm the parameters describing the distributions at each
peak could be updated to accommodate this difference. Beta distributions
have been used in this context by Mu¨ller et al. (2006) to model MALDI-TOF
data although the number of observations in the dataset is small (17 control,
24 tumour). In their analysis the data are interpreted as a histogram and a
mixture model is fitted. However, given the large number of ‘observations’ in
the histogram the results of the analysis should not differ much from those
already presented in this thesis.
5.2.2 Aligning Spectra
In the peak finding algorithm described in chapter 2 one of the main restric-
tions is that the peaks have common locations across all spectra. This is
an important restriction which aids the interpretability of the results and al-
lows comparison. However, it does sometimes result in slightly incorrect peak
heights in the cases where the peak location is not an exact match for that
particular spectrum. In these cases the modelled peak is matching to a point
on the slope of a peak.
If we consider figure 5.2 we can see that this misalignment problem is quite
common. It should also be noted that the misalignments for each of the two
spectra shown in figure 5.2 are in the same direction for all the peaks in the
range (and others not shown). This suggests that there has been a shift in the
spectrum which has moved it a number of m/z values in a particular direction.
The true peaks in figure 5.2 probably lie somewhere between the two examples
shown.
To reduce this problem of shifted spectra we could use an algorithm to
align all of the spectra before analysis starts. One possible method is that of
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dynamic programming as used by Glasbey et al. (2005). Specialised software
is also becoming available for spectrum alignment, e.g. SpecAlign (Wong et
al., 2005).
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Figure 5.2: Plot of a section of the melanoma data and the fitted peaks ob-
tained from the algorithm described in chapter 2. Note that the peaks around
m/z values of 6,450, 6,700 and 7,800 Daltons are misaligned compared to the
original data and this misalignment can occur in both directions.
5.2.3 Further Modelling
As explained at the beginning of chapter 4 it is important to take into account
the complete structure of a dataset if it is known. This was considered in this
thesis by using multilevel modelling to incorporate the hierarchical structure of
the data. Each of the m/z values belongs to a particular spectrum and will be
more similar tom/z values nearby than it will to others from another spectrum.
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This worked well for the melanoma dataset as the structure of the data
is relatively simple and conformed to the two level model explained in sec-
tion 1.6.3. However, for the breast cancer dataset, the structure is not quite
so simple. For this dataset not only do we have a m/z values within spec-
tra hierarchy but there is also information concerning the day the spectrum
was obtained and the experiment number. In this case we could include some
peak/day interactions. By not taking into account the day information when
analysing the breast cancer dataset in chapter 4 it is likely that we will have
obtained an incorrect number of significant results.
Day information for the breast cancer dataset should also be incorporated
into the MCMC work in chapter 3. As the model currently stands, the fact
that the same samples are studied over a period of four days is ignored. To
remedy this a piecewise linear function of time could also be fitted as part of
the MCMC procedure.
Also, further modelling could be carried out in the MLwiN package by con-
sidering Bayesian fitting procedures for multilevel models. This would enable
closer comparisons with the Bayesian approach of chapter 3
5.2.4 Clustering within groups
The ability to classify unknown spectra into the correct groups is important
and could potentially enable physicians to determine the course of treatment
for particular patients. In chapter 2 we achieved a rate of above 80% for cor-
rect classifications of test spectra for both the breast cancer and the melanoma
datasets. However, depending on which spectra were used as training data,
some spectra were misclassified.
The melanoma dataset identifies spectra as belonging to one of two groups
- stage I or stage IV. From looking at the data it has been noted that there
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appears to be more than one type of spectrum present in stage IV. At an m/z
value around 11,700 Da about 25% of the stage IV spectra are very different
to the rest of the spectra in that group.
The presence of different clusters within a particular tumour classification
could be important in identifying certain medical characteristics. For example,
one cluster within the whole group could signify people in which the disease is
more likely to recur in the future. The ability to predict recurrence would be
of great benefit to patients and physicians alike.
5.2.5 Reversible Jump
The breast cancer and melanoma datasets were studied in chapter 3 using a
Bayesian approach which utilised MCMC algorithms. This approach modelled
the spectra as a series of peaks with differing heights and locations. However,
one limitation of the method used in chapter 3 is that the number of peaks
to be found in the data is fixed before any analysis starts. The peaks are
identified using the peak finding algorithm described in chapter 2 which picks
peaks in order of decreasing size. If too few peaks are fitted then this could
result in some small but important peaks being ignored. In the opposite case,
too many peaks could be identified which would cause overfitting to the data.
To remove this dependence on a user-specified number of modelled peaks,
the MCMC algorithm could be adapted to use reversible jump methods. Re-
versible jump MCMC was introduced by Green (1995) as a method to simulate
the posterior distribution when the number of parameters varies. By using
this method, the initial set of peak location parameters can be increased or
decreased at each update by the proposal of a birth or a death step.
For the algorithms used in chapter 3 this would mean that the number of
peaks in the model could become a parameter itself and would not have to
remain restricted to a fixed value - 150 in the current analysis.
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